The
information in this prospectus is not complete and may be changed. We may not sell these securities until the Registration Statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is
not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
Subject
to Completion, dated September 9, 2022
As
filed with the Securities and Exchange Commission on September 9, 2022
Registration
No. 333-
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ADAMIS
PHARMACEUTICALS CORPORATION
(Exact
name of registrant as specified in its charter)
Delaware |
|
82-0429727 |
(State
or other jurisdiction of
incorporation
or organization) |
|
(I.R.S.
Employer
Identification
Number) |
11682
El Camino Real, Suite 300
San Diego, CA
(858) 997-2400
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
David
J. Marguglio
Chief Executive Officer
11682 El Camino Real, Suite 300
San Diego, CA 92130
(858) 997-2400
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies
to:
Teri
O’Brien
Latham & Watkins LLP
12670 High Bluff Drive
San Diego, California 92130
(858) 523-5410
Approximate
date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement,
as the registrant shall determine.
If
the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please
check the following box: ☐
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check
the following box: ☒
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please
check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become
effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐
If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register
additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box. ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
☐ |
|
Accelerated filer |
☐ |
Non-accelerated filer |
☒ |
|
Smaller reporting company |
☒ |
|
|
Emerging growth company |
☐ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
☐
The
registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act or until the Registration Statement shall become effective on such date as the
SEC, acting pursuant to said Section 8(a), may determine.
EXPLANATORY
NOTE
This
Registration Statement of Adamis Pharmaceuticals Corporation (the “Registrant”) contains two prospectuses:
| ● | a
base prospectus which covers the offering, issuance and sale by the Registrant of the
securities identified above from time to time in one or more offerings, which together
shall have an aggregate initial offering price not to exceed $300.0 million; and |
| ● | a
prospectus supplement covering the resale from time to time by the selling stockholder
named in the prospectus supplement (the “Selling Stockholder”) of up to (i) 697,674 shares of our common stock, par value $0.0001 per share (the “Common Stock”),
that are issuable upon the conversion of outstanding shares of our Series C Convertible
Preferred Stock, par value $0.0001 per share (the “Series C Preferred”),
and (ii) 750,000 shares of our Common Stock that are issuable upon the exercise of outstanding
warrants (the “Warrants”) to purchase shares of our Common Stock, both of
which are included in the $300.0 million aggregate offering price set forth in the base
prospectus. The shares of Series C Preferred and Warrants were initially issued in connection
with a private placement, and the shares of Common Stock underlying such securities are
being registered for resale hereby pursuant to the Selling Stockholder’s registration
rights under a registration rights agreement between us and the Selling Stockholder.
|
The
base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the
base prospectus will be specified in one or more prospectus supplements to the base prospectus. A prospectus supplement immediately
follows the base prospectus.
PROSPECTUS
ADAMIS
PHARMACEUTICALS CORPORATION
$300,000,000
Common Stock
Preferred Stock
Debt Securities
Warrants
Units
This prospectus relates to common stock, preferred stock, debt securities,
warrants for debt or equity securities and units consisting of the foregoing that we may sell from time to time in one or more transactions.
In addition, certain selling security holders to be identified in supplements to this prospectus may offer and sell these securities from
time to time. We will provide the specific terms and conditions of these transactions and the securities we or a selling security holder
may sell in supplements to this prospectus prepared in connection with each transaction. The applicable prospectus supplement will contain
information, where applicable, as to other listings, if any, on the Nasdaq Capital Market, or the NASDAQ, or any securities exchange of
the securities covered by the prospectus supplement. Any such prospectus supplement may also add, update or change information in this
prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. You
should carefully read this prospectus, any applicable prospectus supplement and any related free writing prospectuses, as well as the
documents incorporated by reference or deemed to be incorporated by reference into this prospectus, carefully before you invest. This
prospectus may not be used to offer or sell securities unless accompanied by a prospectus supplement.
Our
common stock is traded on the NASDAQ under the symbol “ADMP.”
Investing in our securities involves a high degree
of risk. You should review carefully the risks and uncertainties referenced under the heading “Risk Factors” on page 3 of
this prospectus and contained in our filings made with the Securities and Exchange Commission and the applicable prospectus supplement.
The securities may be sold directly by us to investors
or by any selling security holder from time to time, through agents designated from time to time or to or through underwriters or dealers.
We will provide specific information about any selling security holders in one or more supplements to this prospectus. For additional
information on the methods of sale, you should refer to the section entitled “Plan of Distribution” in this prospectus. If
any underwriters are involved in the sale of these securities with respect to which this prospectus is being delivered, the names of such
underwriters and any applicable commissions or discounts and over-allotment options will be set forth in a prospectus supplement. The
price to the public of such securities and the net proceeds that we expect to receive from such sale will also be set forth in a prospectus
supplement. No securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method
and terms of the offering of such securities.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.
The
date of this prospectus is , 2022.
TABLE
OF CONTENTS
Page
ABOUT
THIS PROSPECTUS
This prospectus is part of a shelf registration statement
on Form S-3 that we filed with the Securities and Exchange Commission, or the SEC, under the Securities Act of 1933, as amended, or the
Securities Act, using a “shelf” registration process. Under this shelf registration process, we may, from time to time, offer
and sell any combination of the securities described in this prospectus in one or more offerings for an aggregate offering amount of up
to $300.0 million. In addition, selling security holders to be named in a prospectus supplement may sell certain of our securities from
time to time.
This prospectus only provides you with a general description
of the securities we may sell in these transactions. Each time we or any selling security holder offers to sell any securities under this
prospectus, we or the selling security holder will provide a prospectus supplement that will contain specific information about the terms
of that offering. The prospectus supplement also may add, update or change information contained in this prospectus. We may also authorize
one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. This prospectus
does not contain all of the information included in the Registration Statement we filed with the SEC. For further information about us
or the securities offered hereby, you should carefully read this prospectus, any applicable prospectus supplement, any related free writing
prospectuses, the information and documents incorporated herein by reference and the additional information under the heading “Where
You Can Find More Information” before making an investment decision.
You
should rely only on the information contained or incorporated by reference in this prospectus, any applicable prospectus supplement
and any related free writing prospectuses that we may authorize to be provided to you. We have not authorized any other person
to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely
on it. This prospectus and any accompanying supplement to this prospectus are not an offer to sell these securities and are not
soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. You should assume that
the information appearing in this prospectus, any applicable prospectus supplement or any related free writing prospectuses, as
well as information we have previously filed with the SEC and incorporated by reference, is accurate only as of the date on the
cover of those documents. If any statement in one of these documents is inconsistent with a statement in another document having
a later date-for example, a document incorporated by reference in this prospectus-the statement in the document having the later
date modifies or supersedes the earlier statement as our business, financial condition, results of operations and prospects may
have changed since the earlier dates.
This
prospectus may not be used to consummate sales of any of these securities unless it is accompanied by a prospectus supplement.
To the extent there are inconsistencies between any prospectus supplement, this prospectus and/or any documents incorporated by
reference, the document with the most recent date will control.
The
Adamis Pharmaceuticals logo and other trademarks or service marks of Adamis Pharmaceuticals Corporation appearing in this prospectus
are the property of Adamis Pharmaceuticals Corporation. All other brand names or trademarks appearing in this prospectus are the
property of their respective owners.
PROSPECTUS
SUMMARY
This
summary description about us and our business highlights selected information contained elsewhere in this prospectus or incorporated
in this prospectus by reference. This summary does not contain all of the information you should consider before buying securities
in this offering. You should carefully read this entire prospectus and any applicable prospectus supplement, including each of
the documents incorporated herein or therein by reference, before making an investment decision. Unless the context otherwise
requires, the terms “Adamis,” “the Company,” “we,” “us” and “our”
in this prospectus refer to Adamis Pharmaceuticals Corporation and its subsidiaries.
Business
Overview of Adamis Pharmaceuticals Corporation
We
are a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including
allergy, opioid overdose, respiratory and inflammatory disease. Our products and product candidates in the allergy, respiratory,
and opioid overdose markets include: SYMJEPI™ (epinephrine) Injection 0.3 mg, which was approved by the U.S. Food and Drug
Administration, or FDA, in 2017 for use in the emergency treatment of acute allergic reactions, including anaphylaxis, for patients
weighing 66 pounds or more; SYMJEPI (epinephrine) Injection 0.15 mg, which was approved by the FDA in September 2018, for use in
the treatment of anaphylaxis for patients weighing 33-65 pounds; ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL, which
was approved by the FDA in October 2021 for the treatment of opioid overdose; and Tempol, an investigational drug. In June 2020,
we entered into a license agreement with a third party to license rights under patents, patent applications and related know-how
of the licensor relating to Tempol. The exclusive license includes the worldwide use under the licensed patent rights and related
rights for the fields of COVID-19 infection, asthma, respiratory syncytial virus infection, and influenza infection, as well as
the use of Tempol as a therapeutic for reducing radiation-induced dermatitis in patients undergoing treatment for cancer. We commenced
Phase 2/3 clinical trial start-up activities to examine the safety and efficacy of Tempol in COVID-19 patients early in the infection,
and on September 2, 2021, we announced the initiation of patient dosing in the trial. In February 2022 we announced the enrollment
and dosing of more than 100 subjects in the Phase 2/3 trial, and on March 14, 2022, we announced that the Data Safety Monitoring
Board, or DSMB, overseeing the Phase 2/3 clinical trial met to evaluate the clinical and safety data from the first planned interim
analysis and, following its evaluation, recommended that the study continue without modification. The DSMB is composed of subject
matter experts and can unblind the data to determine the treatment effects of the subjects in the trial. On June 1, 2022, we announced
that the DSMB had met again to evaluate interim clinical and safety data for the trial and based on an interim review of the data,
determined that the study can continue as planned. On August 10, 2022, we announced that the DSMB is scheduled to meet near the
end of September to review unblinded interim data including safety and efficacy. We will not have access to unblinded trial data
until the trial has concluded and the final study data is compiled and reviewed. At the September meeting, the DSMB plans to evaluate
the primary efficacy endpoint, the sustained resolution of COVID-19 symptoms, as well as safety in individuals who are at high
risk for disease progression. Where applicable, we intend to create low cost therapeutic alternatives to existing treatments and
to submit NDAs under Section 505(b)(2), of the U.S. Food, Drug & Cosmetic Act, as amended, or FDCA, or Section 505(j) Abbreviated
New Drug Applications, or ANDAs, to the FDA, in order to potentially reduce the time to market and to save on costs, compared
to those associated with Section 505(b)(1) NDAs for new drug products.
To
achieve our goals and support our overall strategy, we will need to raise additional funding in the future and make significant
investments in, among other things, product development and working capital.
Corporate
Information
We
are incorporated under the laws of the State of Delaware. Our principal executive offices are located at 11682 El Camino Real,
Suite 300, San Diego, CA 92130, and our telephone number is (858) 997-2400. Our website address is: www.adamispharmaceuticals.com.
We have included our website address as a factual reference and do not intend it to be an active link to our website. The information
that can be accessed through our website is not part of this prospectus, and investors should not rely on any such information
in deciding whether to purchase our securities.
Securities
We May Offer
We
may offer shares of our common stock and preferred stock, debt securities, warrants for debt or equity securities and units consisting
of the foregoing, from time to time under this prospectus, together with any applicable prospectus supplement and related free
writing prospectus, at prices and on terms to be determined by market conditions at the time of offering. This prospectus provides
you with a general description of the securities we may offer. Each time we offer a type or series of securities, we will provide
a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including,
to the extent applicable:
| ● | designation
or classification; |
| ● | aggregate
principal amount or aggregate offering price; |
| ● | maturity,
if applicable; |
| ● | original
issue discount, if any; |
| ● | rates
and times of payment of interest or dividends, if any; |
| ● | redemption,
conversion, exchange or sinking fund terms, if any; |
| ● | conversion
or exchange prices or rates, if any, and, if applicable, any provisions for changes to
or adjustments in the conversion or exchange prices or rates and in the securities or
other property receivable upon conversion or exchange; |
| ● | restrictive
covenants, if any; |
| ● | voting
or other rights, if any; and |
| ● | important
U.S. federal income tax considerations. |
A
prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update
or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement
or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness
of the Registration Statement of which this prospectus is a part.
The
securities may be offered directly by us or by any selling security holder from time to time, through agents designated by us
or to or through underwriters, brokers or dealers. We will provide specific information about any selling security holders in
one or more supplements to this prospectus. We, and our underwriters or agents, reserve the right to accept or reject all or part
of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the applicable
prospectus supplement:
| ● | the
names of those underwriters or agents; |
| ● | applicable
fees, discounts and commissions to be paid to them; |
| ● | details
regarding options to purchase additional securities, if any; and |
RISK
FACTORS
Investment
in our securities involves risks. Prior to making a decision about investing in our securities, you should consider carefully
all of the information included in and incorporated by reference or deemed to be incorporated by reference in this prospectus
or the applicable prospectus supplement, including the risk factors incorporated by reference herein from our Annual Report on
Form 10-K for the year ended December 31, 2021, filed with the SEC on March 31, 2022, as updated by annual, quarterly and other
reports and documents we file with the SEC after the date of this prospectus and that are incorporated by reference herein or
in the applicable prospectus supplement or any free writing prospectus. Each of these risk factors could have a material adverse
effect on our business, results of operations, financial position or cash flows, which may result in the loss of all or part of
your investment. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties
not presently known to us or that we currently consider immaterial may also impair our business operations. If any of these risks
actually occur, our business and financial results could be harmed. In that case, the trading price of our common stock or other
securities could decline. To the extent a particular offering implicates additional known material risks, we will include a discussion
of those risks in the applicable prospectus supplement.
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus and the documents incorporated by reference into this prospectus contain certain forward-looking statements within
the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange
Act, in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements
include, without limitation, statements regarding our future product development and commercialization activities and costs, the
revenue potential (licensing, royalty and sales) of our products and product candidates, the impact of COVID-19 on our business,
the success, safety and efficacy of our drug products, revenues and revenue assumptions, clinical studies, including designs and
implementation, development and commercialization timelines, product acquisitions, accounting principles, litigation expenses,
liquidity and capital resources and trends, and other statements containing forward-looking words, such as, “believes,”
“may,” “could,” “would,” “will,” “expects,” “intends,”
“estimates,” “anticipates,” “plans,” “seeks,” or “continues” or the
negative thereof or variation thereon or similar terminology (although not all forward-looking statements contain these words).
Such forward-looking statements are based on the beliefs of our management as well as assumptions made by and information currently
available to our management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements
are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified; therefore, our actual results
may differ materially from those described in any forward-looking statements.
Factors
that might cause these differences include, but are not limited to, those described in our Annual Report on Form 10-K for the
fiscal year ended December 31, 2021, as updated by annual, quarterly and other reports and documents we file with the SEC, as
well as those discussed elsewhere in this prospectus, and the following factors:
| ● | our
ability to continue as a going concern and ability to raise required additional capital; |
| ● | the
commercial success of our SYMJEPI™ (epinephrine) Injection 0.3 mg and 0.15 mg products,
our ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product, and amounts that
we may receive with respect to sales of such products; |
| ● | future
actions by the FDA and other regulatory agencies regarding our product candidates and
our regulatory filings relating to our product candidates, including without limitation
concerning our Tempol product candidate; |
| ● | the
success of our product research and development programs; |
| ● | our
future development plans concerning our product candidates, and ongoing and planned preclinical
or clinical trials for our product candidates, including the timing of initiation of
these trials, the timing of progress of those trials, anticipated completion dates of
trials, and the results of any such trials, including without limitation the timing and
outcome of our current Phase 2/3 clinical trial relating to our Tempol product candidate; |
| ● | the
timing of, or delay in the timing of, commercial introduction of any of our products; |
| ● | our
ability to enter into collaborations and agreements for the development and commercialization
of our products and product candidates, and the potential benefits of any future commercialization
or collaboration agreements with third parties; |
| ● | regulatory
and personnel issues; |
| ● | our
ability to generate significant revenues; |
| ● | competition
and market developments; |
| ● | the
failure of any of our product candidates, if approved, to achieve commercial success; |
| ● | our
ability to protect our intellectual property from infringement by third parties; |
| ● | the
extent and enforceability of intellectual property rights protections afforded by patents
and patent applications that we own or have licensed; |
| ● | regulatory
and health reform legislation and regulations; |
| ● | the
introduction of technological innovations or new commercial products by our competitors,
and competitive developments in the relevant markets; |
| ● | the
outcome of any legal proceedings in which we are involved or in which we may in the future
become involved; |
| ● | the
effects of public health crises, pandemics and epidemics, such as the COVID-19 pandemic;
and |
| ● | other
risks and uncertainties detailed from time to time in our SEC filings. |
We
urge you to consider these factors carefully in evaluating the forward-looking statements contained in this prospectus and any
prospectus supplement. All subsequent written or oral forward-looking statements attributable to our company or persons acting
on our behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements included
in this prospectus are made only as of the date of this prospectus. We undertake no obligation to update publicly any forward-looking
statements, whether as a result of new information, future events or otherwise, except to the extent that we are required to do
so by law.
USE
OF PROCEEDS
Unless
we indicate otherwise in the applicable prospectus supplement, we anticipate that the net proceeds from the sale of the securities
offered from time to time hereby will be used for general corporate purposes, including, without limitation, research and development
and clinical development costs to support the advancement of our in-development drug candidates, activities in connection with
the launch of our in-development drug candidates, manufacturing, building inventory supply, hiring additional personnel, making
acquisitions of assets, businesses, technologies, products, companies or securities, capital expenditures, the payment, repayment,
refinancing, redemption or repurchase of existing or future indebtedness, and for working capital. When a particular series of
securities is offered, the related prospectus supplement will set forth our intended use of the net proceeds we receive from the
sale of the securities. Pending the application of the net proceeds, we may invest the proceeds in short-term, interest-bearing
instruments or other investment-grade securities. We will not receive any of the proceeds from sales of securities by selling
security holders.
SELLING SECURITY HOLDERS
If the registration statement of which this prospectus forms a part is
used by selling security holders for the resale of any securities registered thereunder pursuant to a registration rights agreement to
be entered into by us with such selling security holders or otherwise, information about such selling security holders, their beneficial
ownership of our securities and their relationship with us will be set forth in a prospectus supplement, any free writing prospectus or
in filings we make with the SEC under the Exchange Act that are incorporated by reference into the registration statement.
DESCRIPTION
OF CAPITAL STOCK WE MAY OFFER
General
Our
authorized capital stock consists of 200,000,000 shares of common stock, par value $0.0001 per share; and 10,000,000 shares of
preferred stock, par value $0.0001 per share.
The
following description of our common stock and preferred stock, together with the additional information included in any applicable
prospectus supplements or related free writing prospectuses, summarizes the material terms and provisions of these types of securities,
but it is not complete. For the complete terms of our common stock and preferred stock, please refer to our restated certificate
of incorporation and our amended and restated bylaws that are incorporated by reference into the Registration Statement which
includes this prospectus and, with respect to preferred stock, any certificate of designation that we may file with the SEC for
a series of preferred stock we may designate.
We
will describe in a prospectus supplement or related free writing prospectuses, the specific terms of any common stock or preferred
stock we may offer pursuant to this prospectus. If indicated in a prospectus supplement, the terms of such common stock or preferred
stock may differ from the terms described below.
Common
Stock
As
of September 8, 2022, there were 149,983,265 shares of common stock outstanding. The holders of our common stock are entitled to one
vote for each share held of record on all matters submitted to a vote of the stockholders; provided, however, that, except as
otherwise required by law, holders of our common stock, as such, shall not be entitled to vote on any amendment to our amended
and restated certificate of incorporation that relates solely to the terms of one or more outstanding series of preferred stock
if the holders of such affected series are entitled, either separately or together with the holders of one or more other such
series, to vote thereon pursuant to our amended and restated certificate of incorporation. The holders of common stock are not
entitled to cumulative voting rights with respect to the election of directors, and as a consequence, minority stockholders will
not be able to elect directors on the basis of their votes alone.
Subject
to preferences that may be applicable to any then outstanding shares of preferred stock, holders of common stock are entitled
to receive ratably such dividends as may be declared by the board of directors out of funds legally available therefor. In the
event of a liquidation, dissolution or winding up of us, holders of the common stock are entitled to share ratably in all assets
remaining after payment of liabilities and the liquidation preferences of any then outstanding shares of preferred stock. Holders
of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption
or sinking fund provisions applicable to our common stock. All outstanding shares of common stock are, and all shares of common
stock to be issued under this prospectus will be, fully paid and non-assessable. The rights, preferences and privileges of holders
of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any of our outstanding
preferred stock.
Listing
Our
common stock is listed under the symbol “ADMP” on the NASDAQ.
Transfer
Agent and Registrar
The
transfer agent and registrar for our common stock is First American Stock Transfer.
Dividends
We
have not declared any cash dividends on our common stock and we do not anticipate paying any cash dividends on our common stock
in the foreseeable future.
Preferred
Stock
We
are authorized to issue a total of 10,000,000 shares of preferred stock. As of September 8, 2022, there were 3,000 shares of Series C
Convertible Preferred Stock (the “Series C Preferred”) issued and outstanding.
Preferred
stock may be issued from time to time, in one or more series, as authorized by the board of directors, without stockholder approval.
The prospectus supplement relating to the preferred shares offered thereby will include specific terms of any preferred shares
offered, including, if applicable:
| ● | the
title of the shares of preferred stock; |
| ● | the
number of shares of preferred stock offered, the liquidation preference per share and
the offering price of the shares of preferred stock; |
| ● | the
dividend rate(s), period(s) and/or payment date(s) or method(s) of calculation thereof
applicable to the shares of preferred stock; |
| ● | whether
the shares of preferred stock are cumulative or not and, if cumulative, the date from
which dividends on the shares of preferred stock shall accumulate; |
| ● | the
procedures for any auction and remarketing, if any, for the shares of preferred stock; |
| ● | the
provision for a sinking fund, if any, for the shares of preferred stock; |
| ● | the
provision for redemption or repurchase, if applicable, and any restrictions on our ability
to exercise those redemption and repurchase rights of the shares of preferred stock; |
| ● | any
listing of the shares of preferred stock on any securities exchange; |
| ● | the
terms and conditions, if applicable, upon which the shares of preferred stock will be
convertible into shares of common stock, including the conversion price (or manner of
calculation thereof); |
| ● | discussion
of federal income tax considerations applicable to the shares of preferred stock; |
| ● | the
relative ranking and preferences of the shares of preferred stock as to dividend rights
and rights upon liquidation, dissolution or winding up of our affairs; |
| ● | any
limitations on issuance of any series or class of shares of preferred stock ranking senior
to or on a parity with such series or class of shares of preferred stock as to dividend
rights and rights upon liquidation, dissolution or winding up of our affairs; |
| ● | any
other specific terms, preferences, rights, limitations or restrictions of the shares
of preferred stock; and |
| ● | any
voting rights of such preferred stock. |
The
transfer agent and registrar for any series or class of preferred stock will be set forth in the applicable prospectus supplement.
Series
C Convertible Preferred Stock
The
preferences and rights of the Series C Preferred are as set forth in a Certificate of Designation of Preferences, Rights and Limitations
of Series C Convertible Preferred Stock (the “Series C Certificate of Designation”) filed as Exhibit 3.1 to our Current
Report on Form 8-K, filed with the SEC on July 6, 2022. The following is a summary of the material terms of our Series C Preferred
and is qualified in its entirety by the Series C Certificate of Designation. Please refer to the Series C Certificate of Designation
for more information on the preferences, rights and limitations of Series C Preferred.
Dividends.
Except for stock dividends or distributions for which adjustments are made pursuant to the Series C Certificate of Designation,
the holders of Series C Preferred will be entitled to dividends, on an as-if converted basis, equal to and in the same form as
dividends actually paid on shares of Common Stock, when, as and if actually paid on shares of Common Stock.
Voting
Rights. Except as otherwise provided in the Series C Certificate of Designation or as otherwise required by law, the Series
C Preferred will have no voting rights (other than the right to vote as a class on certain matters as provided in the Series C
Certificate of Designation). However, each share of Series C Preferred entitles the holder thereof (i) to vote exclusively on
a proposal (the “Proposal”) submitted by the board of directors of the Company to the stockholders to adopt and approve
an amendment to the Company’s restated certificate of incorporation (the “Certificate of Incorporation) to effect
a reverse stock split of the outstanding shares of Common Stock at the ratio set forth in the Proposal that is to be effected
by the filing and effectiveness of a certificate of amendment to the Certificate of Incorporation with the Secretary of State
of the State of Delaware (the “Reverse Stock Split”), and any proposal to adjourn any meeting of stockholders called
for the purpose of voting on the Proposal, and (ii) to 1,000,000 votes per each share of Series C Preferred with respect only
to the foregoing matters. The Series C Preferred shall, except as required by law, vote together with the Common Stock and any
other issued and outstanding shares of preferred stock of the Company entitled to vote, as a single class; provided, however,
that such shares of Series C Preferred shall, to the extent cast, be automatically and without further action of the holders thereof
voted in the same proportion as shares of Common Stock (excluding any shares of Common Stock that are not voted) and any other
issued and outstanding shares of preferred stock of the Company entitled to vote (other than the Series C Preferred or shares
of such preferred stock not voted) are voted on the Proposal and any proposal to adjourn any meeting of stockholders called for
the purpose of voting on the Proposal.
Liquidation,
Dissolution or Winding Up. The Series C Preferred has a “Stated Value” of $100 per share of Series C Preferred.
(i) Upon any liquidation, dissolution or winding up of the Company (a “Liquidation”), the holders of Series C Preferred
are entitled to be paid in cash an amount per share of Series C Preferred equal to 110% of the Stated Value (the “Liquidation
Amount”), or (ii) in the event of a “Deemed Liquidation Event” as defined in the Series C Certificate of Designation,
which generally includes certain merger transactions or a sale, lease or other disposition of all or substantially all of the
assets of the Company, the holders of Series C Preferred are entitled to paid out of the consideration payable to stockholders
in such Deemed Liquidation Event or out of the “Available Proceeds” (as defined in the Series C Certificate of Designation),
in each case before any payment may be made to the holders of Common Stock by reason of their ownership thereof, an amount per
share of Series C Preferred equal to the Liquidation Amount. Upon certain of the Deemed Liquidation Events, if the Company does
not effect a dissolution within 90 days after such event, then the holders of Series C Preferred may require the Company to redeem
the Series C Preferred for an amount equal to the Liquidation Amount.
Conversion.
Each share of Series C Preferred is convertible at the option of the holder, at any time and from time to time after the effective
date of a Reverse Stock Split, into that number of shares (the “Conversion Shares”) of Common Stock (subject to the
Beneficial Ownership Limitation and the Exchange Cap described below) determined by dividing the Stated Value of such share of
Series C Preferred by the Conversion Price then in effect, rounded down to the nearest whole share (with cash paid in lieu of
any fractional shares). The “Conversion Price” for the Series C Preferred equals 90% of the lesser of (i) the closing
sale price of the Common Stock on the trading day immediately prior to the Closing Date and (ii) the average of the closing sale
prices for the Common Stock on the five trading days immediately prior to the Closing Date, subject to adjustment as provided
in the Series C Certificate of Designation; provided, that the Conversion Price may not fall below the par value per share of
the Common Stock and may not exceed $0.60 per share. Based on the initial Conversion Price of $0.43 per share, the 3,000 Shares
of Series C Preferred are initially convertible into approximately 697,674 shares of Common Stock. The Conversion Price is subject
to adjustment as set forth in the Series C Certificate of Designation for stock dividends, stock splits, reverse stock splits,
and similar events. Upon conversion, the shares of Series C Preferred shall resume the status of authorized but unissued shares
of preferred stock of the Company.
Beneficial
Ownership Limitation. The Series C Preferred cannot be converted to Common Stock if the holder and its affiliates would beneficially
own more than 4.99% of the outstanding Common Stock (the “Beneficial Ownership Limitation”). However, any holder may
increase or decrease such percentage to any other percentage not in excess of 9.99% upon notice to us, provided that any increase
in this limitation will not be effective until 61 days after such notice from the holder to us and such increase or decrease will
apply only to the holder providing such notice.
Nasdaq
Issuance Limitation. The Company will not be obligated to issue any shares of Common Stock, and the holders of Series C Preferred
do not have the right to receive, upon conversion, exercise or redemption of the Series C Preferred and the warrants initially
issued to the holder (the “Purchaser”) of the Series C Preferred (the “Warrants”), taken as a whole, any
shares of Common Stock to the extent such issuance of shares of Common Stock would exceed that number of shares of Common Stock
which the Company may issue in the aggregate pursuant to the transactions contemplated under the Securities Purchase Agreement
entered into between the Company and the Purchaser (including pursuant to the Series C Certificate of Designation and the Warrants)
without breaching the Company’s obligations under the rules and regulations of the Nasdaq Capital Markets (the “Exchange
Cap”). In addition, no holder of Series C Preferred shall be issued, in the aggregate pursuant to the terms of the Series
C Certificate of Designation and the Warrants, shares of Common Stock in an amount greater than the product of the Exchange Cap
multiplied by a fraction, the numerator of which is the original Stated Value of such holder’s Series C Preferred and the
denominator of which is the aggregate Stated Value of all Series C Preferred issued on the Closing Date to all holders (with respect
to each holder, the “Exchange Cap Allocation”). In the event that the holder sells or otherwise transfers any of the
holder’s Series C Preferred, the transferee shall be allocated a pro rata portion of the holder’s Exchange Cap Allocation,
and the restrictions of the prior sentence shall apply to such transferee with respect to the portion of the Exchange Cap Allocation
allocated to such transferee. If any holder of Series C Preferred converts all of such holder’s Series C Preferred into
a number of shares of Common Stock which, in the aggregate, is less than such holder’s Exchange Cap Allocation, then the
difference between such holder’s Exchange Cap Allocation and the number of shares of Common Stock actually issued to such
holder will be allocated to the respective Exchange Cap Allocations of the remaining holders of Series C Preferred on a pro rata
basis in proportion to the shares of Series C Preferred then held by each such holder.
Redemption.
Subject to the Purchaser’s right to elect to convert all or a portion of the Series C Preferred at any time following the
effective date of the Reverse Stock Split, the Company may, with the prior notice to the holders of the Series C Preferred specified
in the Series C Certificate of Designation, redeem all or a portion of the Series C Preferred held by such holders at any time
at 105% of the Stated Value, provided, however, that a Company redemption request shall not be effective if received by a holder
of Series C Preferred before the date of the Reverse Stock Split. Each holder of Series C Preferred will have the right, with
the prior notice to the Company as specified in the Series C Certificate of Designation, to require the Company to redeem all
or a portion of the Series C Preferred held by such holder at any time at 110% of the Stated Value, provided, however, that a
holder’s request will not be effective if received by the Company less than five days after the date of a Reverse Stock
Split.
Preemptive
Rights. No holders of Series C Preferred will, as holders of Series C Preferred, have any preemptive rights to purchase or
subscribe for the Common Stock or any of our other securities.
Consent
Rights. In addition to the voting rights of the Series C Preferred described above, as long as any shares of Series C Preferred
are outstanding, the Company shall not, without the affirmative vote of the holders of at least a majority on voting power of
the outstanding shares of Series C Preferred: (a) alter or change adversely the powers, preferences or rights given to the Series
C Preferred or alter or amend the Series C Certificate of Designation, (b) increase the number of authorized shares of Series
C Preferred, or (c) enter into any agreement with respect to any of the foregoing.
Failure
to Deliver Conversion Shares. If the Company fails to timely deliver shares of Common Stock upon conversion of shares of Series
C Preferred within the time period specified in the Series C Certificate of Designation, then the holder is entitled to elect,
by notice to the Company at any time on or before its receipt of such Conversion Shares, to rescind such conversion, and the holder
shall return to the Company any Conversion Shares issued to the holder pursuant to the rescinded notice and the Company shall,
at its own expense, deliver (or cause its transfer agent to deliver) to the converting holder a new book-entry statement, registered
in the name of the holder or its designee, evidencing the number of shares of Series C Preferred owned by the holder immediately
prior to the conversion.
Compensation
for Buy-In on Failure to Timely Deliver Shares. If the Company fails to timely deliver the Conversion Shares to the holder,
and if after the required delivery date the holder is required by its broker to purchase (in an open market transaction or otherwise)
or the holder or its brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the holder
of the Conversion Shares which the holder was entitled to receive upon such conversion, then the Company is obligated to (A) pay
in cash to the holder the amount, if any, by which (x) the holder’s total purchase price (including brokerage commissions,
if any) for the shares of Common Stock so purchased, exceeds (y) the amount obtained by multiplying (1) the number of Conversion
Shares that the Company was required to deliver multiplied by (2) the price at which the sell order giving rise to such purchase
obligation was executed, and (B) at the option of the holder, either reissue (if surrendered) the shares of Series C Preferred
equal to the number of shares submitted for conversion (in which case such conversion shall be deemed rescinded) or deliver to
the holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise
and delivery obligations.
Possible
Anti-Takeover Effects of Delaware Law and our Charter Documents
Provisions
of the Delaware General Corporation Law, or DGCL, our restated certificate of incorporation, and our amended and restated bylaws,
could make it more difficult to acquire us by means of a tender offer, a proxy contest or otherwise, or to remove incumbent officers
and directors. These provisions, summarized below, are expected to discourage certain types of coercive takeover practices and
takeover bids that our board of directors may consider inadequate and to encourage persons seeking to acquire control of us to
first negotiate with our board of directors. We believe that the benefits of increased protection of our ability to negotiate
with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging
takeover or acquisition proposals because, among other things, negotiation of these proposals could result in an improvement of
their terms.
Delaware
Anti-Takeover Statute
We
are subject to Section 203 of the DGCL. This provision generally prohibits a Delaware corporation from engaging in any business
combination with any interested stockholder for a period of three years following the date the stockholder became an interested
stockholder, unless:
|
● |
prior
to such date, the board of directors approved either the business combination or the transaction that resulted in the stockholder
becoming an interested stockholder; |
|
● |
upon
consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder
owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for
purposes of determining the number of shares outstanding those shares owned by persons who are directors and also officers
and by employee stock plans in which employee participants do not have the right to determine confidentially whether shares
held subject to the plan will be tendered in a tender or exchange offer; or |
|
● |
on
or subsequent to such date, the business combination is approved by the board of directors and authorized at an annual meeting
or special meeting of stockholders and not by written consent, by the affirmative vote of at least 66-2/3% of the outstanding
voting stock that is not owned by the interested stockholder. |
Section
203 defines a business combination to include:
|
● |
any
merger or consolidation involving the corporation and the interested stockholder; |
|
● |
any
sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder; |
|
● |
subject
to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation
to the interested stockholder; |
|
● |
any
transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class
or series of the corporation beneficially owned by the interested stockholder; or |
|
● |
the
receipt by the interested stockholder of the direct or indirect benefit of any loans, advances, guarantees, pledges or other
financial benefits provided by or through the corporation. |
In
general, Section 203 defines an “interested stockholder” as any entity or person beneficially owning 15% or more of
the outstanding voting stock of a corporation, or an affiliate or associate of the corporation and was the owner of 15% or more
of the outstanding voting stock of a corporation at any time within three years prior to the time of determination of interested
stockholder status; and any entity or person affiliated with or directly or indirectly controlling or controlled by such entity
or person, who presently holds the power to direct management or is in a director or officer of the corporation.
These
statutory provisions could delay or frustrate the removal of incumbent directors or a change in control of our company, and accordingly,
may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their
stock at a price above the prevailing market price.
Restated
Certificate of Incorporation and Bylaw Provisions
Our
restated certificate of incorporation, as amended, and bylaws contain provisions that could have the effect of discouraging potential
acquisition proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder
might consider favorable. In particular, the restated certificate of incorporation and bylaws, as applicable, among other things:
|
● |
permit
the Board to issue up to 10,000,000 shares of preferred stock, without further action by the stockholders, with any rights,
preferences and privileges as they may designate; |
|
● |
provide
that all vacancies on the Board, including newly created directorships, may, except as otherwise required by law, or as determined
otherwise by resolution of the Board, be filled by the affirmative vote of a majority of directors then in office, even if
less than a quorum; |
|
● |
do
not provide for cumulative voting rights with respect to election of directors; |
|
● |
provide
that no action shall be taken by the stockholders, except at an annual or special meeting of stockholders, and no action shall
be taken by the stockholders by written consent or by electronic transmission; |
|
● |
set
forth an advance notice procedure with regard to the nomination, other than by or at the direction of the Board, of candidates
for election as directors and with regard to business to be brought before a meeting of stockholders. Although the bylaws
do not give the Board the power to approve or disapprove of stockholder nominations of candidates or proposals regarding other
proper business to be conducted at a special or annual meeting, the bylaws may have the effect of precluding the conduct of
certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from
conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of the
Company; and |
|
● |
provide
the Board with the ability to alter its bylaws without stockholder approval. |
Such
provisions may make it more difficult for holders of our common stock to replace our board of directors and may have the effect
of discouraging a third-party from making tender offers for our shares or acquiring us, even if doing so would be beneficial to
our stockholders. These provisions also may have the effect of preventing changes in our management.
Choice
of Forum. Our bylaws provide that unless the corporation consents in writing to the selection of an alternative forum, the
Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for
(i) any derivative action or proceeding brought on behalf of the Company; (ii) any action asserting a claim of breach of a fiduciary
duty owed by any director, officer or other employee of the Company to the Company or the Company’s stockholders; (iii)
any action asserting a claim against the Company or any director or officer or other employee of the Company arising pursuant
to any provision of the DGCL, the certificate of incorporation or the bylaws of the Company, or as to which the DGCL confers jurisdiction
on the Court of Chancery of the State of Delaware; or (iv) any action asserting a claim against the Company or any director or
officer or other employee of the Company governed by the internal affairs doctrine, in all cases subject to the court’s
having personal jurisdiction over the indispensable parties named as defendants (including without limitation as a result of the
consent of such indispensable parties to the personal jurisdiction of such court). The bylaws further provide that if any action
the subject matter of which is within the scope of the preceding sentence is filed in a court other than a court located within
the State of Delaware (a “Foreign Action”) in the name of any stockholder, such stockholder shall be deemed to have
consented to (i) the personal jurisdiction of the state and federal courts located within the State of Delaware in connection
with any action brought in any such court to enforce the preceding sentence; and (ii) having service of process made upon such
stockholder in any such action by service upon such stockholder’s counsel in the Foreign Action as agent for such stockholder.
The bylaws provide that the above provisions do not apply to suits brought to enforce a duty or liability created by the Securities
Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or any other claim for which the federal courts have exclusive jurisdiction. Section 27 of the Exchange Act creates
exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules
and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or
liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Our bylaws
do not relieve us of our duties to comply with federal securities laws and the rules and regulations thereunder, and our stockholders
will not be deemed to have waived our compliance with these laws, rules and regulations. The bylaws also provide that unless the
Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America
shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a
cause of action arising under the Securities Act, and that any person or entity purchasing or otherwise acquiring or holding any
interest in shares of capital stock of the Company shall be deemed to have notice of and consented to the provisions described
above.
Under
the Securities Act, federal and state courts have concurrent jurisdiction over all suits brought to enforce any duty or liability
created by the Securities Act. There is uncertainty as to whether a court (other than state courts in the State of Delaware, where
the Supreme Court of the State of Delaware decided in March 2020 that exclusive forum provisions for causes of action arising
under the Securities Act are facially valid under Delaware law) would enforce forum selection provisions and whether investors
can waive compliance with the federal securities laws and the rules and regulations thereunder. The forum selection provisions
in the bylaws may have the effect of discouraging lawsuits against us and/or our directors, officers and employees as it may limit
any stockholder’s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us
or our directors, officers or employees. In addition, stockholders who do bring a claim in the Court of Chancery in the State
of Delaware could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware.
The enforceability of similar choice of forum provisions in other companies’ charter documents has been challenged in legal
proceedings, and it is possible that, in connection with any applicable action brought against us, a future court could find the
choice of forum provisions contained in our bylaws to be inapplicable or unenforceable in such action. If a court were to find
the choice of forum provision contained in our bylaws to be inapplicable or unenforceable in an action, we may incur additional
costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition
or results of operations.
DESCRIPTION
OF DEBT SECURITIES WE MAY OFFER
The
following description, together with the additional information we include in any applicable prospectus supplement or free writing
prospectus, summarizes certain general terms and provisions of the debt securities that we may offer under this prospectus. When
we offer to sell a particular series of debt securities, we will describe the specific terms of the series in a supplement to
this prospectus. We will also indicate in the supplement to what extent the general terms and provisions described in this prospectus
apply to a particular series of debt securities.
We
may issue debt securities either separately, or together with, or upon the conversion or exercise of or in exchange for, other
securities described in this prospectus. Debt securities may be our senior, senior subordinated or subordinated obligations and,
unless otherwise specified in a supplement to this prospectus, the debt securities will be our direct, unsecured obligations and
may be issued in one or more series.
The
debt securities will be issued under an indenture between us and a trustee named in the prospectus supplement. We have summarized
select portions of the indenture below. The summary is not complete. The form of the indenture has been filed as an exhibit to
the registration statement and you should read the indenture for provisions that may be important to you. In the summary below,
we have included references to the section numbers of the indenture so that you can easily locate these provisions. Capitalized
terms used in the summary and not defined herein have the meanings specified in the indenture.
General
The
terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth
or determined in the manner provided in a resolution of our board of directors, in an officer’s certificate or by a supplemental
indenture. (Section 2.2) The particular terms of each series of debt securities will be described in a prospectus supplement relating
to such series (including any pricing supplement or term sheet).
We
can issue an unlimited amount of debt securities under the indenture that may be in one or more series with the same or various
maturities, at par, at a premium or at a discount. (Section 2.1) We will set forth in a prospectus supplement (including any pricing
supplement or term sheet) relating to any series of debt securities being offered, the aggregate principal amount and the following
terms of the debt securities, if applicable:
| ● | the
title and ranking of the debt securities (including the terms of any subordination provisions); |
| ● | the
price or prices (expressed as a percentage of the principal amount) at which we will
sell the debt securities; |
| ● | any
limit on the aggregate principal amount of the debt securities; |
| ● | the
date or dates on which the principal of the securities of the series is payable; |
| ● | the
rate or rates (which may be fixed or variable) per annum or the method used to determine
the rate or rates (including any commodity, commodity index, stock exchange index or
financial index) at which the debt securities will bear interest, the date or dates from
which interest will accrue, the date or dates on which interest will commence and be
payable and any regular record date for the interest payable on any interest payment
date; |
| ● | the
place or places where principal of, and interest, if any, on the debt securities will
be payable (and the method of such payment), where the debt securities of such series
may be surrendered for registration of transfer or exchange and where notices and demands
to us in respect of the debt securities may be delivered; |
| ● | the
period or periods within which, the price or prices at which and the terms and conditions
upon which we may redeem the debt securities; |
| ● | any
obligation we have to redeem or purchase the debt securities pursuant to any sinking
fund or analogous provisions or at the option of a holder of debt securities and the
period or periods within which, the price or prices at which and in the terms and conditions
upon which securities of the series shall be redeemed or purchased, in whole or in part,
pursuant to such obligation; |
| ● | the
dates on which and the price or prices at which we will repurchase debt securities at
the option of the holders of debt securities and other detailed terms and provisions
of these repurchase obligations; |
| ● | the
denominations in which the debt securities will be issued, if other than denominations
of $1,000 and any integral multiple thereof; |
| ● | whether
the debt securities will be issued in the form of certificated debt securities or global
debt securities; |
| ● | the
portion of principal amount of the debt securities payable upon declaration of acceleration
of the maturity date, if other than the principal amount; |
| ● | the
currency of denomination of the debt securities, which may be United States Dollars or
any foreign currency, and if such currency of denomination is a composite currency, the
agency or organization, if any, responsible for overseeing such composite currency; |
| ● | the
designation of the currency, currencies or currency units in which payment of principal
of, premium and interest on the debt securities will be made; |
| ● | if
payments of principal of, premium or interest on the debt securities will be made in
one or more currencies or currency units other than that or those in which the debt securities
are denominated, the manner in which the exchange rate with respect to these payments
will be determined; |
| ● | the
manner in which the amounts of payment of principal of, premium, if any, or interest
on the debt securities will be determined, if these amounts may be determined by reference
to an index based on a currency or currencies or by reference to a commodity, commodity
index, stock exchange index or financial index; |
| ● | any
provisions relating to any security provided for the debt securities; |
| ● | any
addition to, deletion of or change in the Events of Default described in this prospectus
or in the indenture with respect to the debt securities and any change in the acceleration
provisions described in this prospectus or in the indenture with respect to the debt
securities; |
| ● | any
addition to, deletion of or change in the covenants described in this prospectus or in
the indenture with respect to the debt securities; |
| ● | any
depositaries, interest rate calculation agents, exchange rate calculation agents or other
agents with respect to the debt securities; |
| ● | the
provisions, if any, relating to conversion or exchange of any debt securities of such
series, including if applicable, the conversion or exchange price and period, provisions
as to whether conversion or exchange will be mandatory, the events requiring an adjustment
of the conversion or exchange price and provisions affecting conversion or exchange; |
| ● | any
other terms of the debt securities, which may supplement, modify or delete any provision
of the indenture as it applies to that series, including any terms that may be required
under applicable law or regulations or advisable in connection with the marketing of
the securities; and |
| ● | whether
any of our direct or indirect subsidiaries will guarantee the debt securities of that
series, including the terms of subordination, if any, of such guarantees. (Section 2.2) |
We
may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration
of acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal
income tax considerations and other special considerations applicable to any of these debt securities in the applicable prospectus
supplement.
If
we denominate the purchase price of any of the debt securities in a foreign currency or currencies or a foreign currency unit
or units, or if the principal of and any premium and interest on any series of debt securities is payable in a foreign currency
or currencies or a foreign currency unit or units, we will provide you with information on the restrictions, elections, general
tax considerations, specific terms and other information with respect to that issue of debt securities and such foreign currency
or currencies or foreign currency unit or units in the applicable prospectus supplement.
Transfer
and Exchange
Each
debt security will be represented by either one or more global securities registered in the name of The Depository Trust Company
(DTC or the Depositary), or a nominee of the Depositary (we will refer to any debt security represented by a global debt security
as a “book-entry debt security”), or a certificate issued in definitive registered form (we will refer to any debt
security represented by a certificated security as a “certificated debt security”) as set forth in the applicable
prospectus supplement. Except as set forth under the heading “Global Debt Securities and Book-Entry System” below,
book-entry debt securities will not be issuable in certificated form.
Certificated
Debt Securities. You may transfer or exchange certificated debt securities at any office we maintain for this purpose in accordance
with the terms of the indenture. (Section 2.4) No service charge will be made for any transfer or exchange of certificated debt
securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection
with a transfer or exchange. (Section 2.7)
You
may effect the transfer of certificated debt securities and the right to receive the principal of, premium and interest on certificated
debt securities only by surrendering the certificate representing those certificated debt securities and either reissuance by
us or the trustee of the certificate to the new holder or the issuance by us or the trustee of a new certificate to the new holder.
Global Debt Securities and Book-Entry System. Each global debt security representing book-entry debt securities will be deposited
with, or on behalf of, the Depositary, and registered in the name of the Depositary or a nominee of the Depositary. Please see
“Global Securities.”
Covenants
We
will set forth in the applicable prospectus supplement any restrictive covenants applicable to any issue of debt securities. (Article
IV)
No
Protection in the Event of a Change of Control
Unless
we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions which may afford
holders of the debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction
(whether or not such transaction results in a change in control) which could adversely affect holders of debt securities.
Consolidation,
Merger and Sale of Assets
We
may not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets
to any person (a “successor person”) unless:
| ● | we
are the surviving corporation or the successor person (if other than Icosavax) is a corporation
organized and validly existing under the laws of any U.S. domestic jurisdiction and expressly
assumes our obligations on the debt securities and under the indenture; |
| ● | immediately
after giving effect to the transaction, no Default or Event of Default shall have occurred
and be continuing. |
Notwithstanding
the above, any of our subsidiaries may consolidate with, merge into or transfer all or part of its properties to us. (Section
5.1)
Events
of Default
“Event
of Default” means with respect to any series of debt securities, any of the following:
| ● | default
in the payment of any interest upon any debt security of that series when it becomes
due and payable, and continuance of such default for a period of 30 days (unless the
entire amount of the payment is deposited by us with the trustee or with a paying agent
prior to the expiration of the 30-day period); |
| ● | default
in the payment of principal of any debt security of that series at its maturity; |
| ● | default
in the performance or breach of any other covenant or warranty by us in the indenture
or any debt security (other than a covenant or warranty that has been included in the
indenture solely for the benefit of a series of debt securities other than that series),
which default continues uncured for a period of 60 days after we receive written notice
from the trustee or Icosavax and the trustee receive written notice from the holders
of not less than 25% in principal amount of the outstanding debt securities of that series
as provided in the indenture; |
| ● | certain
voluntary or involuntary events of bankruptcy, insolvency or reorganization of Icosavax;
or |
| ● | any
other Event of Default provided with respect to debt securities of that series that is
described in the applicable prospectus supplement. (Section 6.1) |
No
Event of Default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency
or reorganization) necessarily constitutes an Event of Default with respect to any other series of debt securities. (Section 6.1)
The occurrence of certain Events of Default or an acceleration under the indenture may constitute an event of default under certain
indebtedness of ours or our subsidiaries outstanding from time to time.
We
will provide the trustee written notice of any Default or Event of Default within 30 days of becoming aware of the occurrence
of such Default or Event of Default, which notice will describe in reasonable detail the status of such Default or Event of Default
and what action we are taking or propose to take in respect thereof. (Section 6.1)
If
an Event of Default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee
or the holders of not less than 25% in principal amount of the outstanding debt securities of that series may, by a notice in
writing to us (and to the trustee if given by the holders), declare to be due and payable immediately the principal of (or, if
the debt securities of that series are discount securities, that portion of the principal amount as may be specified in the terms
of that series) and accrued and unpaid interest, if any, on all debt securities of that series. In the case of an Event of Default
resulting from certain events of bankruptcy, insolvency or reorganization, the principal (or such specified amount) of and accrued
and unpaid interest, if any, on all outstanding debt securities will become and be immediately due and payable without any declaration
or other act on the part of the trustee or any holder of outstanding debt securities. At any time after a declaration of acceleration
with respect to debt securities of any series has been made, but before a judgment or decree for payment of the money due has
been obtained by the trustee, the holders of a majority in principal amount of the outstanding debt securities of that series
may rescind and annul the acceleration if all Events of Default, other than the non-payment of accelerated principal and interest,
if any, with respect to debt securities of that series, have been cured or waived as provided in the indenture. (Section 6.2)
We refer you to the prospectus supplement relating to any series of debt securities that are discount securities for the particular
provisions relating to acceleration of a portion of the principal amount of such discount securities upon the occurrence of an
Event of Default.
The
indenture provides that the trustee may refuse to perform any duty or exercise any of its rights or powers under the indenture,
unless the trustee receives indemnity satisfactory to it against any cost, liability or expense which might be incurred by it
in performing such duty or exercising such right or power. (Section 7.1(e)) Subject to certain rights of the trustee, the holders
of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method
and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the
trustee with respect to the debt securities of that series. (Section 6.12)
No
holder of any debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect
to the indenture or for the appointment of a receiver or trustee, or for any remedy under the indenture, unless:
| ● | that
holder has previously given to the trustee written notice of a continuing Event of Default
with respect to debt securities of that series; and |
| ● | the
holders of not less than 25% in principal amount of the outstanding debt securities of
that series have made written request, and offered indemnity or security satisfactory
to the trustee, to the trustee to institute the proceeding as trustee, and the trustee
has not received from the holders of not less than a majority in principal amount of
the outstanding debt securities of that series a direction inconsistent with that request
and has failed to institute the proceeding within 60 days. (Section 6.7) |
Notwithstanding
any other provision in the indenture, the holder of any debt security will have an absolute and unconditional right to receive
payment of the principal of, premium and any interest on that debt security on or after the due dates expressed in that debt security
and to institute suit for the enforcement of payment. (Section 6.8)
The
indenture requires us, within 120 days after the end of our fiscal year, to furnish to the trustee a statement as to compliance
with the indenture. (Section 4.3) If a Default or Event of Default occurs and is continuing with respect to the securities of
any series and if it is known to a responsible officer of the trustee, the trustee shall mail to each holder of the securities
of that series notice of a Default or Event of Default within 90 days after it occurs or, if later, after a responsible officer
of the trustee has knowledge of such Default or Event of Default. The indenture provides that the trustee may withhold notice
to the holders of debt securities of any series of any Default or Event of Default (except in payment on any debt securities of
that series) with respect to debt securities of that series if the trustee determines in good faith that withholding notice is
in the interest of the holders of those debt securities. (Section 7.5)
Modification
and Waiver
We
and the trustee may modify, amend or supplement the indenture or the debt securities of any series without the consent of any
holder of any debt security:
| ● | to
cure any ambiguity, defect or inconsistency; |
| ● | to
comply with covenants in the indenture described above under the heading “Consolidation,
Merger and Sale of Assets”; |
| ● | to
provide for uncertificated securities in addition to or in place of certificated securities; |
| ● | to
add guarantees with respect to debt securities of any series or secure debt securities
of any series; |
| ● | to
surrender any of our rights or powers under the indenture; |
| ● | to
add covenants or events of default for the benefit of the holders of debt securities
of any series; |
| ● | to
comply with the applicable procedures of the applicable depositary; |
| ● | to
make any change that does not adversely affect the rights of any holder of debt securities; |
| ● | to
provide for the issuance of and establish the form and terms and conditions of debt securities
of any series as permitted by the indenture; |
| ● | to
effect the appointment of a successor trustee with respect to the debt securities of
any series and to add to or change any of the provisions of the indenture to provide
for or facilitate administration by more than one trustee; or |
| ● | to
comply with requirements of the SEC in order to effect or maintain the qualification
of the indenture under the Trust Indenture Act. (Section 9.1) |
We
may also modify and amend the indenture with the consent of the holders of at least a majority in principal amount of the outstanding
debt securities of each series affected by the modifications or amendments. We may not make any modification or amendment without
the consent of the holders of each affected debt security then outstanding if that amendment will:
● reduce
the amount of debt securities whose holders must consent to an amendment, supplement or waiver; |
| ● | reduce
the rate of or extend the time for payment of interest (including default interest) on
any debt security; |
| ● | reduce
the principal of or premium on or change the fixed maturity of any debt security or reduce
the amount of, or postpone the date fixed for, the payment of any sinking fund or analogous
obligation with respect to any series of debt securities; |
| ● | reduce
the principal amount of discount securities payable upon acceleration of maturity; |
| ● | waive
a default or event of default in the payment of the principal of, premium or interest
on any debt security (except a rescission of acceleration of the debt securities of any
series by the holders of at least a majority in aggregate principal amount of the then
outstanding debt securities of that series and a waiver of the payment default that resulted
from such acceleration); |
| ● | make
the principal of or premium or interest on any debt security payable in currency other
than that stated in the debt security; |
| ● | make
any change to certain provisions of the indenture relating to, among other things, the
right of holders of debt securities to receive payment of the principal of, premium and
interest on those debt securities and to institute suit for the enforcement of any such
payment and to waivers or amendments; or |
| ● | waive
a redemption payment with respect to any debt security. (Section 9.3) |
Except
for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of
any series may on behalf of the holders of all debt securities of that series waive our compliance with provisions of the indenture.
(Section 9.2) The holders of a majority in principal amount of the outstanding debt securities of any series may on behalf of
the holders of all the debt securities of such series waive any past default under the indenture with respect to that series and
its consequences, except a default in the payment of the principal of, premium or any interest on any debt security of that series;
provided, however, that the holders of a majority in principal amount of the outstanding debt securities of any series may rescind
an acceleration and its consequences, including any related payment default that resulted from the acceleration. (Section 6.13)
Defeasance
of Debt Securities and Certain Covenants in Certain Circumstances
Legal
Defeasance. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities,
we may be discharged from any and all obligations in respect of the debt securities of any series (subject to certain exceptions).
We will be so discharged upon the irrevocable deposit with the trustee, in trust, of money and/or U.S. government obligations
or, in the case of debt securities denominated in a single currency other than U.S. Dollars, government obligations of the government
that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their
terms, will provide money or U.S. government obligations in an amount sufficient in the opinion of a nationally recognized firm
of independent public accountants or investment bank to pay and discharge each installment of principal, premium and interest
on and any mandatory sinking fund payments in respect of, the debt securities of that series on the stated maturity of those payments
in accordance with the terms of the indenture and those debt securities.
This
discharge may occur only if, among other things, we have delivered to the trustee an opinion of counsel stating that we have received
from, or there has been published by, the U.S. Internal Revenue Service a ruling or, since the date of execution of the indenture,
there has been a change in the applicable U.S. federal income tax law, in either case to the effect that, and based thereon such
opinion shall confirm that, the holders of the debt securities of that series will not recognize income, gain or loss for U.S.
federal income tax purposes as a result of the deposit, defeasance and discharge and will be subject to U.S. federal income tax
on the same amounts and in the same manner and at the same times as would have been the case if the deposit, defeasance and discharge
had not occurred. (Section 8.3)
Defeasance
of Certain Covenants. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt
securities, upon compliance with certain conditions:
| ● | we
may omit to comply with the covenant described under the heading “Consolidation,
Merger and Sale of Assets” and certain other covenants set forth in the indenture,
as well as any additional covenants which may be set forth in the applicable prospectus
supplement; and |
| ● | any
omission to comply with those covenants will not constitute a Default or an Event of
Default with respect to the debt securities of that series (“covenant defeasance”). |
The
conditions include:
| ● | depositing
with the trustee money and/or U.S. government obligations or, in the case of debt securities
denominated in a single currency other than U.S. Dollars, government obligations of the
government that issued or caused to be issued such currency, that, through the payment
of interest and principal in accordance with their terms, will provide money in an amount
sufficient in the opinion of a nationally recognized firm of independent public accountants
or investment bank to pay and discharge each installment of principal of, premium and
interest on, and any mandatory sinking fund payments in respect of, the debt securities
of that series on the stated maturity of those payments in accordance with the terms
of the indenture and those debt securities; and |
| ● | delivering
to the trustee an opinion of counsel to the effect that the holders of the debt securities
of that series will not recognize income, gain or loss for United States federal income
tax purposes as a result of the deposit and related covenant defeasance and will be subject
to United States federal income tax on the same amounts and in the same manner and at
the same times as would have been the case if the deposit and related covenant defeasance
had not occurred. (Section 8.4) |
No
Personal Liability of Directors, Officers, Employees or Securityholders
None
of our past, present or future directors, officers, employees or securityholders, as such, will have any liability for any of
our obligations under the debt securities or the indenture or for any claim based on, or in respect or by reason of, such obligations
or their creation. By accepting a debt security, each holder waives and releases all such liability. This waiver and release is
part of the consideration for the issue of the debt securities. However, this waiver and release may not be effective to waive
liabilities under U.S. federal securities laws, and it is the view of the SEC that such a waiver is against public policy.
Governing
Law
The
indenture and the debt securities, including any claim or controversy arising out of or relating to the indenture or the debt
securities, will be governed by the laws of the State of New York.
The
indenture will provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities)
irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding
arising out of or relating to the indenture, the debt securities or the transactions contemplated thereby.
The
indenture will provide that any legal suit, action or proceeding arising out of or based upon the indenture or the transactions
contemplated thereby may be instituted in the federal courts of the United States of America located in the City of New York or
the courts of the State of New York in each case located in the City of New York, and we, the trustee and the holder of the debt
securities (by their acceptance of the debt securities) irrevocably submit to the non-exclusive jurisdiction of such courts in
any such suit, action or proceeding. The indenture will further provide that service of any process, summons, notice or document
by mail (to the extent allowed under any applicable statute or rule of court) to such party’s address set forth in the indenture
will be effective service of process for any suit, action or other proceeding brought in any such court. The indenture will further
provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably and
unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the courts specified above
and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought
in an inconvenient forum. (Section 10.10)
DESCRIPTION
OF WARRANTS WE MAY OFFER
As of September 8, 2022, we had 14,952,824 warrants to purchase shares
of our common stock outstanding. We typically issue warrants to purchase shares of our common stock to investors as part of a financing
transaction, or in connection with services rendered by placement agents and outside consultants.
We
may issue warrants to purchase debt securities, preferred stock, common stock or any combination of the foregoing. We may issue
warrants independently or together with any other securities we offer under a prospectus supplement. The warrants may be attached
to or separate from the securities. We may issue a series of warrants under a separate warrant agreement to be entered into between
a warrant agent and us. The warrant agent will act solely as our agent in connection with the warrants and will not have any obligations
or relationship of agency or trust for or with holders or beneficial owners of warrants. The following outlines some of the general
terms and provisions of the warrants that we may issue from time to time. When we issue warrants, we will provide the specific
terms of the warrants and the applicable warrant agreement in a prospectus supplement and any related free writing prospectuses
and such terms may differ from those described below. To the extent the information contained in the prospectus supplement differs
from this summary description, you should rely on the information in the prospectus supplement. The following description, and
any description of the warrants included in a prospectus supplement, may not be complete and is subject to and qualified in its
entirety by reference to the terms and provisions of the applicable warrant agreement.
Debt
Warrants
We
will describe in the applicable prospectus supplement and any related free writing prospectuses the terms of the debt warrants
being offered, the warrant agreement relating to the debt warrants and the debt warrant certificates representing the debt warrants,
including, as applicable:
| ● | the
title of the debt warrants; |
| ● | the
aggregate number of the debt warrants; |
| ● | the
price or prices at which the debt warrants will be issued; |
| ● | the
designation, aggregate principal amount and terms of the debt securities purchasable
upon exercise of the debt warrants, and the procedures and conditions relating to the
exercise of the debt warrants; |
| ● | the
designation and terms of any related debt securities with which the debt warrants are
issued, and the number of the debt warrants issued with each security; |
| ● | the
date, if any, on and after which the debt warrants and the related debt securities will
be separately transferable; |
| ● | the
principal amount of debt securities purchasable upon exercise of each debt warrant, and
the price at which the principal amount of the debt securities may be purchased upon
exercise; |
| ● | the
date on which the right to exercise the debt warrants will commence, and the date on
which the right will expire; |
| ● | the
maximum or minimum number of the debt warrants that may be exercised at any time; |
| ● | information
with respect to book-entry procedures, if any; |
| ● | changes
to or adjustments in the exercise price of the debt warrants; |
| ● | a
discussion of the material U.S. federal income tax considerations applicable to the exercise
of the debt warrants; and |
| ● | any
other terms of the debt warrants and terms, procedures and limitations relating to the
exercise of the debt warrants. |
As
may be permitted under the warrant agreement, holders may exchange debt warrant certificates for new debt warrant certificates
of different denominations, and may exercise debt warrants at the corporate trust office of the warrant agent or any other office
indicated in the applicable prospectus supplement and any related free writing prospectuses. Prior to the exercise of their debt
warrants, holders of debt warrants will not have any of the rights of holders of the securities purchasable upon the exercise
and will not be entitled to payments of principal, premium or interest on the securities purchasable upon the exercise of debt
warrants.
Equity
Warrants
We
will describe in the applicable prospectus supplement and any related free writing prospectuses the terms of the preferred stock
warrants or common stock warrants being offered, the warrant agreement relating to the preferred stock warrants or common stock
warrants and the warrant certificates representing the preferred stock warrants or common stock warrants, including, as applicable:
| ● | the
title of the warrants; |
| ● | the
securities for which the warrants are exercisable; |
| ● | the
price or prices at which the warrants will be issued; |
| ● | if
applicable, the number of warrants issued with each share of preferred stock or share
of common stock; |
| ● | if
applicable, the date on and after which the warrants and the related preferred stock
or common stock will be separately transferable; |
| ● | the
date on which the right to exercise the warrants will commence, and the date on which
the right will expire; |
| ● | the
maximum or minimum number of warrants which may be exercised at any time; |
| ● | information
with respect to book-entry procedures, if any; |
| ● | a
discussion of the material U.S. federal income tax considerations applicable to exercise
of the warrants; and |
| ● | any
other terms of the warrants, including terms, procedures and limitations relating to
the exchange and exercise of the warrants. |
Unless
otherwise provided in the applicable warrant agreement and corresponding prospectus supplement or any related free writing prospectuses,
holders of equity warrants will not be entitled, by virtue of being such holders, to vote, consent, receive dividends, receive
notice as stockholders with respect to any meeting of stockholders for the election of our directors or any other matter, or to
exercise any rights whatsoever as stockholders.
Except
as provided in the applicable warrant agreement and corresponding prospectus supplement or any related free writing prospectuses,
the exercise price payable and the number of shares of common stock or preferred stock purchasable upon the exercise of each warrant
will be subject to adjustment in certain events, including the issuance of a stock dividend to holders of common stock or preferred
stock or a stock split, reverse stock split, combination, subdivision or reclassification of common stock or preferred stock.
In lieu of adjusting the number of shares of common stock or preferred stock purchasable upon exercise of each warrant, we may
elect to adjust the number of warrants. Unless otherwise provided in the applicable warrant agreement and corresponding prospectus
supplement or any related free writing prospectuses, no adjustments in the number of shares purchasable upon exercise of the warrants
will be required until all cumulative adjustments require an adjustment of at least 1% thereof. No fractional shares will be issued
upon exercise of warrants, but we will pay the cash value of any fractional shares otherwise issuable. Notwithstanding the foregoing,
except as otherwise provided in the applicable warrant agreement and corresponding prospectus supplement or any related free writing
prospectuses, in case of any consolidation, merger, or sale or conveyance of our property as an entirety or substantially as an
entirety, the holder of each outstanding warrant will have the right to the kind and amount of shares of stock and other securities
and property, including cash, receivable by a holder of the number of shares of common stock or preferred stock into which each
warrant was exercisable immediately prior to the particular triggering event.
Exercise
of Warrants
Each
warrant will entitle the holder of the warrant to purchase for cash at the exercise price provided in the applicable warrant agreement
and corresponding prospectus supplement or any related free writing prospectuses the principal amount of debt securities or shares
of preferred stock or shares of common stock being offered. Holders may exercise warrants at any time up to the close of business
on the expiration date provided in the applicable warrant agreement and corresponding prospectus supplement or any related free
writing prospectuses. After the close of business on the expiration date, unexercised warrants are void.
Holders
may exercise warrants as described in the applicable warrant agreement and corresponding prospectus supplement or any free writing
prospectuses relating to the warrants being offered. Upon receipt of payment and the warrant certificate properly completed and
duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable warrant agreement
and corresponding prospectus supplement or any related free writing prospectuses, we will, as soon as practicable, forward the
debt securities, shares of preferred stock or shares of common stock purchasable upon the exercise of the warrant. If less than
all of the warrants represented by the warrant certificate are exercised, we will issue a new warrant certificate for the remaining
warrants.
DESCRIPTION
OF UNITS WE MAY OFFER
The
following description, together with the additional information we may include in any applicable prospectus supplements and free
writing prospectuses, summarizes the material terms and provisions of the units that we may offer under this prospectus. While
the terms we have summarized below will apply generally to any units that we may offer under this prospectus, we will describe
the particular terms of any series of units in more detail in the applicable prospectus supplement. The terms of any units offered
under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally
change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus
at the time of its effectiveness.
We
will file as exhibits to the Registration Statement of which this prospectus is a part, or will incorporate by reference from
a current report on Form 8-K that we file with the SEC, the form of unit agreement that describes the terms of the series of units
we are offering, and any supplemental agreements, before the issuance of the related series of units. The following summaries
of material terms and provisions of the units are subject to, and qualified in their entirety by reference to, all the provisions
of the unit agreement and any supplemental agreements applicable to a particular series of units. We urge you to read the applicable
prospectus supplements related to the particular series of units that we sell under this prospectus, as well as the complete unit
agreement and any supplemental agreements that contain the terms of the units.
General
We
may issue units comprised of one or more shares of common stock, shares of preferred stock, debt securities and warrants in any
combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit.
Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under
which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any
time or at any time before a specified date.
We
will describe in the applicable prospectus supplement the terms of the series of units, including:
| ● | the
designation and terms of the units and of the securities comprising the units, including
whether and under what circumstances those securities may be held or transferred separately; |
| ● | any
provisions of the governing unit agreement that differ from those described below; and |
| ● | any
provisions for the issuance, payment, settlement, transfer or exchange of the units or
of the securities comprising the units. |
The
provisions described in this section, as well as those described under “Description of Capital Stock We May Offer,”
“Description of Debt Securities We May Offer” and “Description of Warrants We May Offer” will apply to
each unit and to any common stock, preferred stock, debt security or warrant included in each unit, respectively.
Issuance
in Series
We
may issue units in such amounts and in numerous distinct series as we determine.
Enforceability
of Rights by Holders of Units
Each
unit agent, if any, will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship
of agency or trust with any holder of any unit. A single bank or trust company may act as unit agent for more than one series
of units. A unit agent will have no duty or responsibility in case of any default by us under the applicable unit agreement or
unit, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any
holder of a unit may, without the consent of the related unit agent or the holder of any other unit, enforce by appropriate legal
action its rights as holder under any security included in the unit.
We,
the unit agents and any of their agents may treat the registered holder of any unit certificate as an absolute owner of the units
evidenced by that certificate for any purpose and as the person entitled to exercise the rights attaching to the units so registered,
despite any notice to the contrary.
GLOBAL
SECURITIES
Book-Entry,
Delivery and Form
Unless
we indicate differently in any applicable prospectus supplement or free writing prospectus, the securities initially will be issued
in book-entry form and represented by one or more global notes or global securities, or, collectively, global securities. The
global securities will be deposited with, or on behalf of DTC and registered in the name of Cede & Co., the nominee of DTC.
Unless and until it is exchanged for individual certificates evidencing securities under the limited circumstances described below,
a global security may not be transferred except as a whole by the depositary to its nominee or by the nominee to the depositary,
or by the depositary or its nominee to a successor depositary or to a nominee of the successor depositary.
DTC
has advised us that it is:
|
● |
|
a
limited-purpose trust company organized under the New York Banking Law; |
|
● |
|
a
“banking organization” within the meaning of the New York Banking Law; |
|
● |
|
a
member of the Federal Reserve System; |
|
● |
|
a
“clearing corporation” within the meaning of the New York Uniform Commercial Code; and |
|
● |
|
a
“clearing agency” registered pursuant to the provisions of Section 17A of the Exchange Act. |
DTC
holds securities that its participants deposit with DTC. DTC also facilitates the settlement among its participants of securities
transactions, such as transfers and pledges, in deposited securities through electronic computerized book-entry changes in participants’
accounts, thereby eliminating the need for physical movement of securities certificates. “Direct participants” in
DTC include securities brokers and dealers, including underwriters, banks, trust companies, clearing corporations and other organizations.
DTC is a wholly-owned subsidiary of The Depository Trust & Clearing Corporation (DTCC). DTCC is the holding company for DTC,
National Securities Clearing Corporation and Fixed Income Clearing Corporation, all of which are registered clearing agencies.
DTCC is owned by the users of its regulated subsidiaries. Access to the DTC system is also available to others, which we sometimes
refer to as indirect participants, that clear through or maintain a custodial relationship with a direct participant, either directly
or indirectly. The rules applicable to DTC and its participants are on file with the SEC.
Purchases
of securities under the DTC system must be made by or through direct participants, which will receive a credit for the securities
on DTC’s records. The ownership interest of the actual purchaser of a security, which we sometimes refer to as a beneficial
owner, is in turn recorded on the direct and indirect participants’ records. Beneficial owners of securities will not receive
written confirmation from DTC of their purchases. However, beneficial owners are expected to receive written confirmations providing
details of their transactions, as well as periodic statements of their holdings, from the direct or indirect participants through
which they purchased securities. Transfers of ownership interests in global securities are to be accomplished by entries made
on the books of participants acting on behalf of beneficial owners. Beneficial owners will not receive certificates representing
their ownership interests in the global securities, except under the limited circumstances described below.
To
facilitate subsequent transfers, all global securities deposited by direct participants with DTC will be registered in the name
of DTC’s partnership nominee, Cede & Co., or such other name as may be requested by an authorized representative of
DTC. The deposit of securities with DTC and their registration in the name of Cede & Co. or such other nominee will not change
the beneficial ownership of the securities. DTC has no knowledge of the actual beneficial owners of the securities. DTC’s
records reflect only the identity of the direct participants to whose accounts the securities are credited, which may or may not
be the beneficial owners. The participants are responsible for keeping account of their holdings on behalf of their customers.
So
long as the securities are in book-entry form, you will receive payments and may transfer securities only through the facilities
of the depositary and its direct and indirect participants. We will maintain an office or agency in the location specified in
the prospectus supplement for the applicable securities, where notices and demands in respect of the securities and the indenture
may be delivered to us and where certificated securities may be surrendered for payment, registration of transfer or exchange.
Conveyance
of notices and other communications by DTC to direct participants, by direct participants to indirect participants and by direct
participants and indirect participants to beneficial owners will be governed by arrangements among them, subject to any legal
requirements in effect from time to time.
Redemption
notices will be sent to DTC. If less than all of the securities of a particular series are being redeemed, DTC’s practice
is to determine by lot the amount of the interest of each direct participant in the securities of such series to be redeemed.
Neither
DTC nor Cede & Co. (or such other DTC nominee) will consent or vote with respect to the securities. Under its usual procedures,
DTC will mail an omnibus proxy to us as soon as possible after the record date. The omnibus proxy assigns the consenting or voting
rights of Cede & Co. to those direct participants to whose accounts the securities of such series are credited on the record
date, identified in a listing attached to the omnibus proxy.
So
long as securities are in book-entry form, we will make payments on those securities to the depositary or its nominee, as the
registered owner of such securities, by wire transfer of immediately available funds. If securities are issued in definitive certificated
form under the limited circumstances described below and unless if otherwise provided in the description of the applicable securities
herein or in the applicable prospectus supplement, we will have the option of making payments by check mailed to the addresses
of the persons entitled to payment or by wire transfer to bank accounts in the United States designated in writing to the applicable
trustee or other designated party at least 15 days before the applicable payment date by the persons entitled to payment, unless
a shorter period is satisfactory to the applicable trustee or other designated party.
Redemption
proceeds, distributions and dividend payments on the securities will be made to Cede & Co., or such other nominee as may be
requested by an authorized representative of DTC. DTC’s practice is to credit direct participants’ accounts upon DTC’s
receipt of funds and corresponding detail information from us on the payment date in accordance with their respective holdings
shown on DTC records. Payments by participants to beneficial owners will be governed by standing instructions and customary practices,
as is the case with securities held for the account of customers in bearer form or registered in “street name.” Those
payments will be the responsibility of participants and not of DTC or us, subject to any statutory or regulatory requirements
in effect from time to time. Payment of redemption proceeds, distributions and dividend payments to Cede & Co., or such other
nominee as may be requested by an authorized representative of DTC, is our responsibility; disbursement of payments to direct
participants is the responsibility of DTC; and disbursement of payments to the beneficial owners is the responsibility of direct
and indirect participants.
Except
under the limited circumstances described below, purchasers of securities will not be entitled to have securities registered in
their names and will not receive physical delivery of securities. Accordingly, each beneficial owner must rely on the procedures
of DTC and its participants to exercise any rights under the securities and the indenture.
The
laws of some jurisdictions may require that some purchasers of securities take physical delivery of securities in definitive form.
Those laws may impair the ability to transfer or pledge beneficial interests in securities.
DTC
may discontinue providing its services as securities depositary with respect to the securities at any time by giving reasonable
notice to us. Under such circumstances, in the event that a successor depositary is not obtained, securities certificates are
required to be printed and delivered.
As
noted above, beneficial owners of a particular series of securities generally will not receive certificates representing their
ownership interests in those securities. However, if:
| ● | DTC
notifies us that it is unwilling or unable to continue as a depositary for the global
security or securities representing such series of securities or if DTC ceases to be
a clearing agency registered under the Exchange Act at a time when it is required to
be registered and a successor depositary is not appointed within 90 days of the notification
to us or of our becoming aware of DTC’s ceasing to be so registered, as the case
may be; |
| ● | we
determine, in our sole discretion, not to have such securities represented by one or
more global securities; or |
| ● | an
Event of Default has occurred and is continuing with respect to such series of securities, |
we
will prepare and deliver certificates for such securities in exchange for beneficial interests in the global securities. Any beneficial
interest in a global security that is exchangeable under the circumstances described in the preceding sentence will be exchangeable
for securities in definitive certificated form registered in the names that the depositary directs. It is expected that these
directions will be based upon directions received by the depositary from its participants with respect to ownership of beneficial
interests in the global securities.
Euroclear
and Clearstream
If
so provided in the applicable prospectus supplement, you may hold interests in a global security through Clearstream Banking S.A.,
which we refer to as “Clearstream,” or Euroclear Bank S.A./N.V., as operator of the Euroclear System, which we refer
to as “Euroclear,” either directly if you are a participant in Clearstream or Euroclear or indirectly through organizations
which are participants in Clearstream or Euroclear. Clearstream and Euroclear will hold interests on behalf of their respective
participants through customers’ securities accounts in the names of Clearstream and Euroclear, respectively, on the books
of their respective U.S. depositaries, which in turn will hold such interests in customers’ securities accounts in such
depositaries’ names on DTC’s books.
Clearstream
and Euroclear are securities clearance systems in Europe. Clearstream and Euroclear hold securities for their respective participating
organizations and facilitate the clearance and settlement of securities transactions between those participants through electronic
book-entry changes in their accounts, thereby eliminating the need for physical movement of certificates.
Payments,
deliveries, transfers, exchanges, notices and other matters relating to beneficial interests in global securities owned through
Euroclear or Clearstream must comply with the rules and procedures of those systems. Transactions between participants in Euroclear
or Clearstream, on one hand, and other participants in DTC, on the other hand, are also subject to DTC’s rules and procedures.
Investors
will be able to make and receive through Euroclear and Clearstream payments, deliveries, transfers and other transactions involving
any beneficial interests in global securities held through those systems only on days when those systems are open for business.
Those systems may not be open for business on days when banks, brokers and other institutions are open for business in the United
States.
Cross-market
transfers between participants in DTC, on the one hand, and participants in Euroclear or Clearstream, on the other hand, will
be effected through DTC in accordance with the DTC’s rules on behalf of Euroclear or Clearstream, as the case may be, by
their respective U.S. depositaries; however, such cross-market transactions will require delivery of instructions to Euroclear
or Clearstream, as the case may be, by the counterparty in such system in accordance with the rules and procedures and within
the established deadlines (European time) of such system. Euroclear or Clearstream, as the case may be, will, if the transaction
meets its settlement requirements, deliver instructions to its U.S. depositary to take action to effect final settlement on its
behalf by delivering or receiving interests in the global securities through DTC, and making or receiving payment in accordance
with normal procedures for same-day fund settlement. Participants in Euroclear or Clearstream may not deliver instructions directly
to their respective U.S. depositaries.
Due
to time zone differences, the securities accounts of a participant in Euroclear or Clearstream purchasing an interest in a global
security from a direct participant in DTC will be credited, and any such crediting will be reported to the relevant participant
in Euroclear or Clearstream, during the securities settlement processing day (which must be a business day for Euroclear or Clearstream)
immediately following the settlement date of DTC. Cash received in Euroclear or Clearstream as a result of sales of interests
in a global security by or through a participant in Euroclear or Clearstream to a direct participant in DTC will be received with
value on the settlement date of DTC but will be available in the relevant Euroclear or Clearstream cash account only as of the
business day for Euroclear or Clearstream following DTC’s settlement date.
Other
The
information in this section of this prospectus concerning DTC, Clearstream, Euroclear and their respective book-entry systems
has been obtained from sources that we believe to be reliable, but we do not take responsibility for this information. This information
has been provided solely as a matter of convenience. The rules and procedures of DTC, Clearstream and Euroclear are solely within
the control of those organizations and could change at any time. Neither we nor the trustee nor any agent of ours or of the trustee
has any control over those entities and none of us takes any responsibility for their activities. You are urged to contact DTC,
Clearstream and Euroclear or their respective participants directly to discuss those matters. In addition, although we expect
that DTC, Clearstream and Euroclear will perform the foregoing procedures, none of them is under any obligation to perform or
continue to perform such procedures and such procedures may be discontinued at any time. Neither we nor any agent of ours will
have any responsibility for the performance or nonperformance by DTC, Clearstream and Euroclear or their respective participants
of these or any other rules or procedures governing their respective operations.
PLAN
OF DISTRIBUTION
We, or the applicable selling security holders, may sell the offered securities
from time to time.
| ● | to
or through underwriters; |
| ● | to
or through broker-dealers (acting as agent or principal); |
| ● | in
“at the market offerings” within the meaning of Rule 415(a)(4) of the Securities
Act; |
| ● | directly
to purchasers, through a specific bidding or auction process or otherwise; or |
| ● | through
a combination of these methods of sale. |
The
applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) will describe
the terms of the offering of the securities, including:
| ● | the
name or names of any underwriters, if any, and if required, any dealers or agents and
the amount of shares underwritten or purchased by each of them; |
| ● | the
purchase price or other consideration to be paid in connection with the sale of the securities
being offered and the proceeds we will receive from the sale; |
| ● | any
underwriting discounts or agency fees and other items constituting underwriters’
or agents’ compensation; |
| ● | any
over-allotment options under which underwriters may purchase additional securities from
us; |
| ● | any
discounts or concessions allowed or reallowed or paid to dealers; and |
| ● | any
securities exchange or market on which the securities may be listed. |
We
may distribute the securities from time to time in one or more transactions at:
| ● | fixed
price or prices, which may be changed from time to time; |
| ● | market
prices prevailing at the time of sale; |
| ● | prices
related to such prevailing market prices; or |
Only
underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement.
If
we utilize an underwriter in the sale of the securities being offered, we will execute an underwriting agreement with the underwriter
at the time of sale. Any underwriters used in the sale will acquire the securities for their own account and may resell the securities
from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of
sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters
or by underwriters without a syndicate.
In
connection with the sale of the securities, we, or the purchasers of the securities for whom the underwriter may act as agent,
may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the securities to
or through dealers, and the underwriter may compensate those dealers in the form of discounts, concessions or commissions. Subject
to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement.
We may change from time to time the public offering price and any discounts or concessions allowed or reallowed or paid to dealers.
We
may directly solicit offers to purchase the securities. We may also designate agents to solicit offers to purchase the securities
from time to time. We will name in a prospectus supplement any agent involved in the offer or sale of our securities. Unless the
prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment.
If
we utilize a dealer in the sale of the securities being offered by this prospectus, we will sell the securities to the dealer,
as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the
time of resale.
We
and/or the selling security holders, if applicable, may authorize agents or underwriters to solicit offers by institutional
investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed
delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these
contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.
Underwriters,
dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of
the Securities Act, and any discounts and commissions received by them and any profit realized by them on resale of the securities
may be deemed to be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and
agents against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required
to make in respect thereof.
In
addition, we may enter into derivative transactions with third parties (including the writing of options), or sell securities
not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement
indicates, in connection with such a transaction, the third parties may, pursuant to this prospectus and the applicable prospectus
supplement, sell securities covered by this prospectus and the applicable prospectus supplement. If so, the third party may use
securities borrowed from us or others to settle such sales and may use securities received from us to close out any related short
positions. We may also loan or pledge securities covered by this prospectus and the applicable prospectus supplement to third
parties, who may sell the loaned securities or, in an event of default in the case of a pledge, sell the pledged securities pursuant
to this prospectus and the applicable prospectus supplement. The third party in such sale transactions will be an underwriter
and will be identified in the applicable prospectus supplement or in a post-effective amendment.
All
securities we offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters
may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without
notice. We cannot guarantee the liquidity of the trading markets for any securities. Shares of our common stock sold pursuant
to the Registration Statement of which this prospectus is a part will be authorized for listing and trading on the NASDAQ. The
applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on the NASDAQ or
any securities market or other securities exchange of the securities covered by the prospectus supplement.
Underwriters
may engage in stabilizing and syndicate covering transactions in accordance with Rule 104 under the Exchange Act. Rule 104 permits
stabilizing bids to purchase the securities being offered as long as the stabilizing bids do not exceed a specified maximum. Underwriters
may over-allot the offered securities in connection with the offering, thus creating a short position in their account. Syndicate
covering transactions involve purchases of the offered securities by underwriters in the open market after the distribution has
been completed in order to cover syndicate short positions. Underwriters may also cover an over-allotment or short position by
exercising their over-allotment option, if any. Stabilizing and syndicate covering transactions may cause the price of the offered
securities to be higher than it would otherwise be in the absence of these transactions. These transactions, if commenced, may
be discontinued at any time.
Any
underwriters who are qualified market makers on the NASDAQ may engage in passive market making transactions in the securities
on the NASDAQ in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before
the commencement of offers or sales of the common stock. Passive market makers must comply with applicable volume and price limitations
and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess
of the highest independent bid for such security; if all independent bids are lowered below the passive market maker’s bid,
however, the passive market maker’s bid must then be lowered when certain purchase limits are exceeded.
The
underwriters, dealers and agents may engage in other transactions with us, or perform other services for us, in the ordinary course
of their business. We will describe such relationships in the prospectus supplement naming the underwriter and the nature of any
such relationship.
LEGAL
MATTERS
The
validity of the securities being offered hereby will be passed on by Latham & Watkins, LLP, San Diego, California. Any underwriters,
dealers or agents will also be advised about the validity of the securities and other legal matters by their own counsel, which
will be named in the prospectus supplement.
EXPERTS
The consolidated financial statements as of December 31, 2021 and 2020
and for each of the two years in the period ended December 31, 2021 incorporated by reference in this prospectus have been so incorporated
in reliance on the report of BDO USA, LLP, an independent registered public accounting firm, incorporated herein by reference, given on
the authority of said firm as experts in auditing and accounting. The report on the consolidated financial statements contains an explanatory
paragraph regarding the Company's ability to continue as a going concern.
WHERE
YOU CAN FIND MORE INFORMATION
We
are a reporting company and file annual, quarterly and current reports, proxy and information statements and other information
with the SEC. This prospectus is part of a Registration Statement that we have filed with the SEC relating to the securities to
be offered under this prospectus. This prospectus does not contain all of the information set forth in the Registration Statement
and the exhibits to the Registration Statement. For further information with respect to us and the securities to be offered under
this prospectus, we refer you to the Registration Statement and the exhibits and schedules filed as a part of the Registration
Statement. The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding
issuers that file electronically with the SEC, where you may read and copy the Registration Statement, as well as our reports,
proxy and information statements and other information. The address of the SEC’s web site is www.sec.gov. We maintain
a website at www.adamispharmaceuticals.com. Information contained in or accessible through our website does not constitute
a part of this prospectus.
INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE
The
SEC allows us to incorporate by reference into this prospectus certain information we file with it, which means that we can disclose
important information by referring you to those documents. The information incorporated by reference is considered to be a part
of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained
in this prospectus and any accompanying prospectus supplement. We incorporate by reference the documents listed below that we
have previously filed with the SEC (excluding any portions of any Form 8-K that are not deemed “filed” pursuant to
the General Instructions of Form 8-K):
| ● | our Annual Report on Form
10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 31, 2022, and the amendment there to filed
on Form 10-K/A on May
2, 2022; |
| ● | our Quarterly Report on Form
10-Q for the quarter ended March 31, 2022, as filed with the SEC on May 13, 2021; |
| ● | our Quarterly Report on Form
10-Q for the quarter ended June 30, 2022, as filed with the SEC on August 10, 2022; |
| ● | our Current Reports on Form 8-K, as filed with the SEC on January
4, 2022, January
10, 2022, February
18, 2022, March
3, 2022, March 28,
2022, March 31,
2022, April 11,
2022, May 9, 2022,
May 16, 2022, May
19, 2022, May 26,
2022, June 17, 2022,
June 24, 2022, July
6, 2022, July 29, 2022,
August 1, 2022 and August
17, 2022; and |
| ● | the description of our common stock contained in our Form 8-A
filed on December 11, 2013, including any amendments thereto or reports filed for the purposes of updating this description. |
We
also incorporate by reference any future filings (other than Current Reports furnished under Items 2.02 or 7.01 of Form 8-K and
exhibits filed on such form that are related to such items unless such Form 8-K expressly provides to the contrary) made with
the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial filing of the registration
statement of which this prospectus is a part and prior to effectiveness of the registration statement, and (ii) after the effectiveness
of the registration statement but prior to the termination of the offering of the securities covered by this prospectus, excluding,
in each case, information deemed furnished and not filed.
Any statement contained in this prospectus, or in a document incorporated
or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded to the extent that a statement contained
herein, or in any subsequently filed document that also is incorporated or deemed to be incorporated by reference herein, modifies or
supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute
a part of this prospectus.
We
will provide to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request,
at no cost to the requester, a copy of any and all of the information that is incorporated by reference in this prospectus.
Requests
for such documents should be directed to:
Adamis Pharmaceuticals Corporation
11682 El Camino Real, Suite 300
San Diego, California 92130
Attention: Corporate Secretary
You
may also access the documents incorporated by reference in this prospectus through our website at www.adamispharmaceuticals.com.
Except for the specific incorporated documents listed above, no information available on or through our website shall be deemed
to be incorporated in this prospectus or the registration statement of which it forms a part.
Statements
contained in this prospectus as to the contents of any contract or other documents are not necessarily complete, and in each instance
investors are referred to the copy of the contract or other document filed as an exhibit to the Registration Statement, each such
statement being qualified in all respects by such reference and the exhibits and schedules thereto.
ADAMIS
PHARMACEUTICALS CORPORATION
$300,000,000
Common Stock
Preferred Stock
Debt Securities
Warrants
Units
PROSPECTUS
, 2022
SUBJECT
TO COMPLETION, DATED SEPTEMBER 9, 2022
PROSPECTUS
The information in this
prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting
an offer to buy these securities in any state where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED SEPTEMBER 9, 2022
PROSPECTUS
ADAMIS PHARMACEUTICALS CORPORATION
697,674 Shares of Common Stock Underlying
Series C Convertible Preferred Stock
750,000 Shares of Common Stock Underlying
Warrants
This prospectus relates to the resale from time to time by the selling
stockholder named in this prospectus (the “Selling Stockholder”) of up to (i) 697,674 shares of our common stock, par value
$0.0001 per share (the “Common Stock”), that are issuable upon the conversion of outstanding shares of our Series C Convertible
Preferred Stock, par value $0.0001 per share (the “Series C Preferred”), and (ii) 750,000 shares of our Common Stock that
are issuable upon the exercise of outstanding warrants (the “Warrants”) to purchase shares of our Common Stock. The shares
of Series C Preferred and Warrants were initially issued in connection with a private placement, and the shares of Common Stock underlying
such securities are being registered for resale hereby pursuant to the Selling Stockholder’s registration rights under a registration
rights agreement between us and the Selling Stockholder.
The Selling Stockholder
may offer, sell or distribute all or a portion of its shares of our Common Stock publicly or through private transactions at prevailing
market prices or at negotiated prices. We will not receive any of the proceeds from the sale of the shares of our Common Stock
owned by the Selling Stockholder. We will bear all costs, expenses and fees in connection with the registration of these shares
of our common stock, including with regard to compliance with state securities or “blue sky” laws. The Selling Stockholder
will bear all commissions and discounts, if any, attributable to its sale of shares of our Common Stock.
Our Common Stock is listed on the Nasdaq Capital Market under the symbol
“ADMP”. On September 7, 2022, the last reported sale price of our Common Stock was $0.33 per share.
Investing in our securities
involves a high degree of risk. You should review carefully the risks and uncertainties referenced under the heading “Risk
Factors” on page 4 of this prospectus and contained in our filings made with the Securities and Exchange Commission before
investing in our securities.
Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus is , 2022.
TABLE OF CONTENTS
Page
ABOUT
THIS PROSPECTUS
This
prospectus is part of a registration statement on Form S-3 that we filed with the United States Securities and Exchange Commission,
or the SEC, using a “shelf” registration process. Under this shelf registration process, the Selling Stockholder may,
from time to time, sell up to (i) up to 697,674 shares of our Common Stock upon the conversion of the outstanding Series C Preferred
and (ii) 750,000 shares of our Common Stock upon the exercise of the outstanding Warrants as described in this prospectus.
This prospectus and the
documents incorporated into this prospectus by reference include important information about us, the shares being offered by the
Selling Stockholder and other information you should know before investing in our Common Stock. To the extent there is a conflict
between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated
by reference into this prospectus that was filed with the SEC before the date of this prospectus, on the other hand, you should
rely on the information in this prospectus. However, if any statement in one of these documents is inconsistent with a statement
in another document having a later date-for example, a document incorporated by reference in this prospectus-the statement in the
document having the later date modifies or supersedes the earlier statement as our business, financial condition, results of operations
and prospects may have changed since the earlier dates.
We further note that the
representations, warranties and covenants made by us in any agreement, including the Purchase Agreement (as defined below), that
is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties
to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreement, and should
not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were
accurate only as of the date when made. Accordingly such representations, warranties and covenants should not be relied on as accurately
representing the current state of our affairs.
You should rely on this
prospectus and the information incorporated or deemed to be incorporated by reference into this prospectus. We have not authorized,
and the Selling Stockholder has not authorized, anyone to provide you with information that is in addition to or different from
that contained or incorporated by reference into this prospectus. Neither we nor the Selling Stockholder takes responsibility for,
or can provide assurance as to the reliability of, any other information that others may give you. The Selling Stockholder will
not make an offer to sell or seek offers to buy shares of our Common Stock in any jurisdiction where offers and sales are not permitted.
You should not assume that the information contained or incorporated by reference in this prospectus is accurate as of any date
other than as of the date of this prospectus or in the case of the documents incorporated by reference, the date of such documents
regardless of the time of delivery of this prospectus or any sale of our Common Stock. Our business, financial condition, liquidity,
results of operations and prospects may have changed since those dates. You should read this prospectus, the documents incorporated
by reference into this prospectus, and any free writing prospectus that we may authorize for use in connection with this offering,
in their entirety before making an investment decision. You should also read and consider the information in the documents to which
we have referred you in the sections of this prospectus titled “Where You Can Find More Information” and “Incorporation
of Certain Documents by Reference.”
The Adamis Pharmaceuticals
logo and other trademarks or service marks of Adamis Pharmaceuticals Corporation appearing in this prospectus are the property
of Adamis Pharmaceuticals Corporation. All other brand names or trademarks appearing in this prospectus are the property of their
respective owners.
PROSPECTUS
SUMMARY
This summary description
about us and our business highlights selected information contained elsewhere in this prospectus or incorporated in this prospectus
by reference. This summary does not contain all of the information you should consider before buying our securities. You should
carefully read this entire prospectus, including each of the documents incorporated herein by reference, before making an investment
decision. Unless the context otherwise requires, the terms “Adamis,” “the Company,” “we,” “us”
and “our” in this prospectus refer to Adamis Pharmaceuticals Corporation and its subsidiaries.
Business Overview of
Adamis Pharmaceuticals Corporation
We are a specialty biopharmaceutical
company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory
and inflammatory disease. Our products and product candidates in the allergy, respiratory, and opioid overdose markets include:
SYMJEPI™ (epinephrine) Injection 0.3mg, which was approved by the U.S. Food and Drug Administration, or FDA, in 2017 for
use in the emergency treatment of acute allergic reactions, including anaphylaxis, for patients weighing 66 pounds or more; SYMJEPI
(epinephrine) Injection 0.15mg, which was approved by the FDA in September 2018, for use in the treatment of anaphylaxis for patients
weighing 33-65 pounds; ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL, which was approved by the FDA in October 2021 for
the treatment of opioid overdose; and Tempol, an investigational drug. In June 2020, we entered into a license agreement with a
third party to license rights under patents, patent applications and related know-how of the licensor relating to Tempol. The exclusive
license includes the worldwide use under the licensed patent rights and related rights for the fields of COVID-19 infection, asthma,
respiratory syncytial virus infection, and influenza infection, as well as the use of Tempol as a therapeutic for reducing radiation-induced
dermatitis in patients undergoing treatment for cancer. We commenced Phase 2/3 clinical trial start-up activities to examine the
safety and efficacy of Tempol in COVID-19 patients early in the infection, and on September 2, 2021, we announced the initiation
of patient dosing in the trial. In February 2022 we announced the enrollment and dosing of more than 100 subjects in the Phase
2/3 trial, and on March 14, 2022, we announced that the Data Safety Monitoring Board, or DSMB, overseeing the Phase 2/3 clinical
trial met to evaluate the clinical and safety data from the first planned interim analysis and, following its evaluation, recommended
that the study continue without modification. The DSMB is composed of subject matter experts and can unblind the data to determine
the treatment effects of the subjects in the trial. On June 1, 2022, we announced that the DSMB had met again to evaluate interim
clinical and safety data for the trial and based on an interim review of the data, determined that the study can continue as planned.
On August 10, 2022, we announced that the DSMB is scheduled to meet near the end of September to review unblinded interim data
including safety and efficacy. We will not have access to unblinded trial data until the trial has concluded and the final study
data is compiled and reviewed. At the September meeting, the DSMB plans to evaluate the primary efficacy endpoint, the sustained
resolution of COVID-19 symptoms, as well as safety in individuals who are at high risk for disease progression. Where applicable,
we intend to create low cost therapeutic alternatives to existing treatments and to submit NDAs under Section 505(b)(2), of the
U.S. Food, Drug & Cosmetic Act, as amended, or FDCA, or Section 505(j) Abbreviated New Drug Applications, or ANDAs, to the
FDA, in order to potentially reduce the time to market and to save on costs, compared to those associated with Section 505(b)(1)
NDAs for new drug products.
To achieve our goals and
support our overall strategy, we will need to raise additional funding in the future and make significant investments in, among
other things, product development and working capital.
Private Placement of
Shares of Preferred Stock and Warrants
The following is a summary
of the transaction relating to the securities being registered hereunder:
On July 5, 2022, the
Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC
(the “Selling Stockholder”), pursuant to which the Company issued to the Selling Stockholder, in a private placement
transaction (the “Offering”), an aggregate of (i) 3,000 shares of Series C Convertible Preferred Stock, par value
$0.0001 per share (the “Series C Preferred”), initially convertible into 697,674
shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and (ii) warrants
to purchase up to an aggregate of 750,000 shares of Common Stock (the “Warrants”), at an exercise price of $0.47 per
share (subject to adjustment as provided in the Warrants), for an aggregate subscription amount equal to $300,000. The Warrants
become exercisable commencing January 3, 2023, and have a term ending on January 5, 2028.
In connection with the
Offering, the Company entered into the Registration Rights Agreement with the Selling Stockholder (the “Registration Rights
Agreement”). Pursuant to the terms of the Registration Rights Agreement and subject to certain restrictions, all shares of
Common Stock issued and issuable upon conversion in full of the Series C Preferred and exercise in full of the Warrants (together
with any additional shares of Common Stock issued and issuable in connection with any anti-dilution provisions in the Series C
Preferred or the Warrants and any securities issued or issuable upon any stock split, dividend or other distribution, recapitalization
or similar event with respect to the foregoing) are entitled to registration rights (collectively, the “Registrable Securities”).
The Registration Rights
Agreement provides that (i) in the event all of the Series C Preferred has not been redeemed, the Company will, within 30 calendar
days following the effective date of the Reverse Stock Split Amendment (as defined in the Registration Rights Agreement), or (ii)
in the event that all of the Series C Preferred has been fully redeemed, the Company will, within 120 calendar days following the
date of the Purchase Agreement, prepare and file with the SEC a registration statement covering the resale of all of the Registrable
Securities. The Company will use its commercially reasonable efforts to have such registration statement declared effective as
promptly as possible after the filing thereof, but in any event no later than (A) the 60th calendar day following the effective
date of the Reverse Stock Split Amendment (or in the event of a “full review” by the SEC, the 90th calendar day following
the effective date of the Reverse Stock Split Amendment), in the event all of the Series C Preferred has not been fully redeemed,
or (B) the 150th calendar day following the date of the Purchase Agreement (or in the event of a “full review” by the
SEC, the 180th calendar day following the date of the Purchase Agreement), in the event all of the Series C Preferred has been
fully redeemed. The Company will bear the expenses incurred in connection with the filing of any registration statements filed
pursuant to the terms of the Registration Rights Agreement. The Company and the Stockholder agree in the Registration Rights Agreement
to provide customary indemnification in connection with any offerings of Common Stock effected pursuant to the terms of the Registration
Rights Agreement.
Corporate Information
We are incorporated under
the laws of the State of Delaware. Our principal executive offices are located at 11682 El Camino Real, Suite 300, San Diego, CA
92130, and our telephone number is (858) 997-2400. Our website address is: www.adamispharmaceuticals.com. We have included our
website address as a factual reference and do not intend it to be an active link to our website. The information that can be accessed
through our website is not part of this prospectus, and investors should not rely on any such information in deciding whether to
purchase our Common Stock.
THE
OFFERING
| Issuer | Adamis
Pharmaceuticals Corporation |
| | |
| Shares of Common Stock Offered | |
| By the Selling Stockholder | Up to 1,447,674
shares of Common Stock |
| | |
| Use of proceeds | We will not receive any
proceeds from the sale of shares of Common Stock by the Selling Stockholder |
| | |
| Risk factors | Investing
in our securities involves a high degree of risk. See “Risk Factors” beginning
on page 4 of this prospectus and under a similar heading in any documents included or incorporated
by reference herein. |
| | |
| Nasdaq Capital Market symbol | “ADMP.” |
RISK
FACTORS
Investment in our securities
involves risks. Prior to making a decision about investing in our securities, you should consider carefully all of the information
included in and incorporated by reference or deemed to be incorporated by reference in this prospectus, including the risk factors
incorporated by reference herein from our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on
March 31, 2022, as updated by annual, quarterly and other reports and documents we file with the SEC after the date of this prospectus
and that are incorporated by reference herein. Each of these risk factors could have a material adverse effect on our business,
results of operations, financial position or cash flows, which may result in the loss of all or part of your investment. The risks
and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us
or that we currently consider immaterial may also impair our business operations. If any of these risks actually occur, our business
and financial results could be harmed. In that case, the trading price of our Common Stock or other securities could decline.
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus and the
documents incorporated by reference into this prospectus contain certain forward-looking statements within the meaning of Section
27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, in reliance
upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without
limitation, statements regarding our future product development and commercialization activities and costs, the revenue potential
(licensing, royalty and sales) of our products and product candidates, the impact of COVID-19 on our business, the success, safety
and efficacy of our drug products, revenues and revenue assumptions, clinical studies, including designs and implementation, development
and commercialization timelines, product acquisitions, accounting principles, litigation expenses, liquidity and capital resources
and trends, and other statements containing forward-looking words, such as, “believes,” “may,” “could,”
“would,” “will,” “expects,” “intends,” “estimates,” “anticipates,”
“plans,” “seeks,” or “continues” or the negative thereof or variation thereon or similar terminology
(although not all forward-looking statements contain these words). Such forward-looking statements are based on the beliefs of
our management as well as assumptions made by and information currently available to our management. Readers should not put undue
reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some
of which cannot be predicted or quantified; therefore, our actual results may differ materially from those described in any forward-looking
statements.
Factors that might cause
these differences include, but are not limited to, those described in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2021, as updated by annual, quarterly and other reports and documents we file with the SEC, as well as those discussed
elsewhere in this prospectus, and the following factors:
| ● | our ability to continue as a going concern and ability to raise required additional capital; |
| ● | the commercial success of our SYMJEPI™ (epinephrine) Injection 0.3mg and 0.15 mg products, our
ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product, and amounts that we may receive with respect to sales of such products; |
| ● | future actions by the FDA and other regulatory agencies regarding our product candidates and our regulatory
filings relating to our product candidates, including without limitation concerning our Tempol product candidate; |
| ● | the success of our product research and development programs; |
| ● | our future development plans concerning our product candidates, and ongoing and planned preclinical
or clinical trials for our product candidates, including the timing of initiation of these trials, the timing of progress of those
trials, anticipated completion dates of trials, and the results of any such trials, including without limitation the timing and
outcome of our current Phase 2/3 clinical trial relating to our Tempol product candidate; |
| ● | the timing of, or delay in the timing of, commercial introduction of any of our products; |
| ● | our ability to enter into collaborations and agreements for the development and commercialization
of our products and product candidates, and the potential benefits of any future commercialization or collaboration agreements
with third parties; |
| ● | regulatory and personnel issues; |
| ● | our ability to generate significant revenues; |
| ● | competition and market developments; |
| ● | the failure of any of our product candidates, if approved, to achieve commercial success; |
| ● | our ability to protect our intellectual property from infringement by third parties; |
| ● | the extent and enforceability of intellectual property rights protections afforded by patents and
patent applications that we own or have licensed; |
| ● | regulatory and health reform legislation and regulations; |
| ● | the introduction of technological innovations or new commercial products by our competitors, and competitive
developments in the relevant markets; |
| ● | the outcome of any legal proceedings in which we are involved or in which we may in the future become
involved; |
| ● | the effects of public health crises, pandemics and epidemics, such as the COVID-19 pandemic; and |
| ● | other risks and uncertainties detailed from time to time in our SEC filings. |
We urge you to consider
these factors carefully in evaluating the forward-looking statements contained in this prospectus. All subsequent written or oral
forward-looking statements attributable to our company or persons acting on our behalf are expressly qualified in their entirety
by these cautionary statements. The forward-looking statements included in this prospectus are made only as of the date of this
prospectus. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information,
future events or otherwise, except to the extent that we are required to do so by law.
USE
OF PROCEEDS
We are filing this prospectus
pursuant to our contractual obligation under the Registration Rights Agreement to the Selling Stockholder. We will not receive
any of the proceeds from the resale of shares of our Common Stock from time to time by the Selling Stockholder.
A portion of the shares covered by this prospectus
are issuable upon exercise of the Warrants to purchase shares of Common Stock. Pursuant to conditions set forth in the Warrants, the Warrants
are exercisable under certain circumstances on a cashless basis, and should the Selling Stockholder elect to exercise on a cashless basis
we will not receive any proceeds from the sale of Common Stock issued upon the cashless exercise of the Warrants. The holders of the Warrants
are not obligated to exercise their Warrants, and we cannot predict whether holders of the Warrants will choose to exercise all or any
of their Warrants or if they will do so for cash or on a cashless basis. However, if all of the Warrants were exercised for cash, we would
receive gross proceeds of approximately $325,500. We currently intend to use such proceeds, if any, for working capital and general corporate
purposes.
The Selling Stockholder will pay any expenses incurred
by the Selling Stockholder for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholder
in disposing of these shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered
by this prospectus, including, without limitation, all registration fees, listing fees of the Nasdaq Capital Market and fees and expenses
of our counsel and our accountants.
PLAN
OF DISTRIBUTION
The Selling Stockholder
and any of its pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered
hereby on the principal trading market or any other stock exchange, market or trading facility on which the securities are traded
or in private transactions. These sales may be at fixed or negotiated prices. The Selling Stockholder may use any one or more of
the following methods when selling securities:
| ● | ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; |
| ● | block trades in which the broker-dealer will attempt to sell the securities as agent but may position
and resell a portion of the block as principal to facilitate the transaction; |
| ● | purchases by a broker-dealer as principal and resale by the broker-dealer for its account; |
| ● | an exchange distribution in accordance with the rules of the applicable exchange; |
| ● | privately negotiated transactions; |
| ● | settlement of short sales; |
| ● | in transactions through broker-dealers that agree with the Selling Stockholder to sell a specified
number of such securities at a stipulated price per security; |
| ● | through the writing or settlement of options or other hedging transactions, whether through an options
exchange or otherwise; |
| ● | a combination of any such methods of sale; or |
| ● | any other method permitted pursuant to applicable law. |
The Selling Stockholder
may also sell securities under Rule 144 or any other exemption from registration under the Securities Act of 1933, as amended (the
“Securities Act”), if available, rather than under this prospectus.
Broker-dealers engaged
by the Selling Stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction
not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction
a markup or markdown in compliance with FINRA Rule 2121.
In connection with the
sale of the securities or interests therein, the Selling Stockholder may enter into hedging transactions with broker-dealers or
other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions
they assume. The Selling Stockholder may also sell securities short and deliver these securities to close out their short positions,
or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholder may also enter
into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities
which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which
securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended
to reflect such transaction).
The Selling Stockholder
and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters” within
the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. The Selling Stockholder has informed the Company that it does not have any written or oral agreement
or understanding, directly or indirectly, with any person to distribute the securities.
The Company is required
to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed
to indemnify the Selling Stockholder against certain losses, claims, damages and liabilities, including liabilities under the Securities
Act.
We agreed to keep this
prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholder without
registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for
the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of
similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or
any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if
required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be
sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification
requirement is available and is complied with.
Under applicable rules
and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously
engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation
M, prior to the commencement of the distribution. In addition, the Selling Stockholder will be subject to applicable provisions
of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and
sales of the common stock by the Selling Stockholder or any other person. We will make copies of this prospectus available to the
Selling Stockholder and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the
time of the sale (including by compliance with Rule 172 under the Securities Act).
SELLING
STOCKHOLDER
The Common Stock being
offered by the Selling Stockholder are those shares previously issued or issuable to the Selling Stockholder upon conversion of
the Series C Preferred and exercise of the Warrants. For additional information regarding the issuances of those securities, see
“Private Placement of Shares of Preferred Stock and Warrants” above. We are registering the shares of Common
Stock in order to permit the Selling Stockholder to offer the shares for resale from time to time. Except for the ownership of
the shares of Common Stock, Series C Preferred and the Warrants, the Selling Stockholder has not had any material relationship
with us within the past three years.
The first two columns
in the table below provide the name of the Selling Stockholder and the number of shares of our Common Stock beneficially owned
by the Selling Stockholder prior to this offering, without regard to any limitations on exercises. The number of shares reflected
are those beneficially owned by the Selling Stockholders and the information is not necessarily indicative of beneficial ownership
for any other purpose. Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person
has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security,
including options and warrants that are currently exercisable or exercisable within 60 days.
The third column in the
table below lists the shares of Common Stock being offered pursuant to this prospectus by the Selling Stockholder. We have assumed
that all shares of Common Stock reflected in the table as being offered in the offering covered by this prospectus will be sold
from time to time in this offering. We cannot provide an estimate as to the number of shares of Common Stock that will actually
be held by the Selling Stockholder upon termination of the offering covered by this prospectus because the Selling Stockholder
may offer some, all or none of its shares of Common Stock being offered in the offering.
In accordance with the
terms of the Registration Rights Agreement, this prospectus generally covers the resale of the maximum number of shares of Common
Stock issued and issuable upon conversion of the Series C Preferred and exercise of the Warrants, determined as if the outstanding
shares of Series C Preferred and Warrants were converted or exercised in full as of the trading day immediately preceding the date
this registration statement was initially filed with the SEC, without regard to any limitations on the conversion of the Series
C Preferred or exercise of the Warrants.
Under the terms of the
Series C Preferred and Warrants, a Selling Stockholder may not convert or exercise, as applicable, shares of Series C Preferred
and/or Warrants to the extent such conversion or exercise would cause such Selling Stockholder, together with its affiliates and
attribution parties, to beneficially own a number of shares of Common Stock which would exceed 4.99% or 9.99%, as applicable, of
our then outstanding Common Stock following such exercise, excluding for purposes of such determination shares of Common Stock
issuable upon conversion of such Series C Preferred and exercise of such Warrants which have not been exercised. The number of
shares in the second and fourth columns below do not reflect this limitation. The Selling Stockholder may sell all, some or none
of its shares in this offering. See “Plan of Distribution.”
Name of Selling
Shareholder |
Number of shares of
Common Stock
Owned Prior to
Offering |
Maximum Number
of shares of Common
Stock to be Sold
Pursuant to this
Prospectus |
Number of shares of Common
Stock Owned After Offering |
Lincoln Park Capital Fund, LLC |
2,547,674(1) |
1,447,674(2) |
1,100,000 |
| (1) | Includes 697,674 shares of Common Stock that are issuable upon conversion of the shares of Series C Preferred held by the Selling
Stockholder, and 750,000 shares of Common Stock that are issuable upon exercise of the Warrants held by the Selling Stockholder. Also
includes 1,100,000 shares Common Stock that are issuable upon exercise of warrants held by the Selling Stockholder other than the Warrants.
Lincoln Park Capital, LLC (“LPC”) is the Managing Member of Lincoln Park Capital Fund LLC (“Lincoln Park”). Rockledge
Capital Corporation (“RCC”) and Alex Noah Investors, LLC (“Alex Noah”) are the managing Members of LPC. Josh Scheinfeld
is the president and sole shareholder of RCC as well as a principal of LPC. Mr. Cope is the president and sole shareholder of Alex Noah,
as well as a principal of LPC. As a result of the foregoing, Mr. Scheinfeld and Mr. Cope have shared voting and shared investment power
over shares of Common Stock of the Company held directly by Lincoln Park. The address of Lincoln Park is 440 N. Wells Street, Suite 410,
Chicago, Illinois 60654. |
| (2) | Assumes that the Selling Stockholder disposes of all of the shares of Common Stock covered by this prospectus and does not acquire
beneficial ownership of any additional shares. The registration of these shares does not necessarily mean that the Selling Stockholders
will sell all or any portion of the shares covered by this prospectus. |
LEGAL
MATTERS
The validity of the securities
offered by this prospectus will be passed upon by Latham & Watkins LLP, San Diego, CA.
EXPERTS
The consolidated financial statements as of December 31, 2021 and 2020
and for each of the two years in the period ended December 31, 2021 incorporated by reference in this prospectus have been so incorporated
in reliance on the report of BDO USA, LLP, an independent registered public accounting firm, incorporated herein by reference, given on
the authority of said firm as experts in auditing and accounting. The report on the consolidated financial statements contains an explanatory
paragraph regarding the Company's ability to continue as a going concern.
WHERE
YOU CAN FIND MORE INFORMATION
We are a reporting company
and file annual, quarterly and current reports, proxy and information statements and other information with the SEC. This prospectus
is part of a Registration Statement that we have filed with the SEC relating to the securities to be offered under this prospectus.
This prospectus does not contain all of the information set forth in the Registration Statement and the exhibits to the Registration
Statement. For further information with respect to us and the securities to be offered under this prospectus, we refer you to the
Registration Statement and the exhibits and schedules filed as a part of the Registration Statement. The SEC maintains an internet
site that contains reports, proxy and information statements, and other information regarding issuers that file electronically
with the SEC, where you may read and copy the Registration Statement, as well as our reports, proxy and information statements
and other information. The address of the SEC’s web site is www.sec.gov. We maintain a website at www.adamispharmaceuticals.com.
Information contained in or accessible through our website does not constitute a part of this prospectus.
INFORMATION
INCORPORATED BY REFERENCE
The SEC allows us to incorporate by reference
into this prospectus certain information we file with it, which means that we can disclose important information by referring you
to those documents. The information incorporated by reference is considered to be a part of this prospectus, and information that
we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying
prospectus supplement. We incorporate by reference the documents listed below that we have previously filed with the SEC (excluding
any portions of any Form 8-K that are not deemed “filed” pursuant to the General Instructions of Form 8-K):
| ● | our Annual Report on Form
10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 31, 2022, and the amendment there to filed
on Form 10-K/A on May
2, 2022; |
| ● | our Quarterly Report on Form
10-Q for the quarter ended March 31, 2022, as filed with the SEC on May 13, 2021; |
| ● | our Quarterly Report on Form
10-Q for the quarter ended June 30, 2022, as filed with the SEC on August 10, 2022; |
| ● | our Current Reports on Form 8-K, as filed with the SEC on January
4, 2022, January
10, 2022, February
18, 2022, March
3, 2022, March 28,
2022, March 31,
2022, April 11,
2022, May 9, 2022,
May 16, 2022, May
19, 2022, May 26,
2022, June 17, 2022,
June 24, 2022, July
6, 2022, July 29, 2022,
August 1, 2022 and August
17, 2022; and |
| ● | the description of our common stock contained in our Form 8-A
filed on December 11, 2013, including any amendments thereto or reports filed for the purposes of updating this description. |
We also incorporate by
reference any future filings (other than Current Reports furnished under Items 2.02 or 7.01 of Form 8-K and exhibits filed on such
form that are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant to Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial filing of the registration statement of which this
prospectus is a part and prior to effectiveness of the registration statement, and (ii) after the effectiveness of the registration
statement but prior to the termination of the offering of the securities covered by this prospectus, excluding, in each case, information
deemed furnished and not filed.
Any statement contained
in this prospectus, or in a document incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified
or superseded to the extent that a statement contained herein, or in any subsequently filed document that also is incorporated
or deemed to be incorporated by reference herein, modifies or supersedes such statement. Any statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
We will provide to each
person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, at no cost to the requester,
a copy of any and all of the information that is incorporated by reference in this prospectus.
Requests
for such documents should be directed to:
Adamis Pharmaceuticals Corporation
11682 El Camino Real, Suite 300
San Diego, California 92130
Attention: Corporate Secretary
You may also access the
documents incorporated by reference in this prospectus through our website at www.adamispharmaceuticals.com. Except for
the specific incorporated documents listed above, no information available on or through our website shall be deemed to be incorporated
in this prospectus or the registration statement of which it forms a part.
ADAMIS PHARMACEUTICALS CORPORATION
697,674 Shares of Common Stock Underlying
Series C Convertible Preferred Stock
750,000 Shares of Common Stock Underlying
Warrants
PROSPECTUS
, 2022
Part II
Information Not Required in Prospectus
Item 14. Other Expenses
of Issuance and Distribution
The following table sets
forth the estimated costs and expenses (other than the actual registration fee), other than underwriting discounts and commissions,
payable by the Registrant in connection with the sale of the securities being registered
Securities and Exchange Commission registration fee | |
$ | 27,810 | |
FINRA filing fee | |
| * | |
Accounting fees and expenses | |
| * | |
Legal fees and expenses | |
| * | |
Transfer agent fees and expenses | |
| * | |
Printing and miscellaneous expenses | |
| * | |
Total | |
$ | * | |
*These fees are calculated
based on the number of issuances and amount of securities offered and accordingly cannot be estimated at this time. An estimate
of the aggregate amount of these expenses will be reflected in the applicable prospectus supplement.
Item 15. Indemnification
of Directors and Officers
Section 145 of the Delaware
General Corporation Law, or the DGCL, provides that a corporation may indemnify directors and officers as well as other employees
and individuals against expenses including attorneys’ fees, judgments, fines and amounts paid in settlement in connection
with various actions, suits or proceedings, whether civil, criminal, administrative or investigative other than an action by or
in the right of the corporation, a derivative action, if they acted in good faith and in a manner they reasonably believed to be
in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, if they had
no reasonable cause to believe their conduct was unlawful. A similar standard is applicable in the case of derivative actions,
except that indemnification only extends to expenses including attorneys’ fees incurred in connection with the defense or
settlement of such actions, and the statute requires court approval before there can be any indemnification where the person seeking
indemnification has been found liable to the corporation. The statute provides that it is not exclusive of other indemnification
that may be granted by a corporation’s certificate of incorporation, bylaws, agreement, a vote of stockholders or disinterested
directors or otherwise. Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation’s
board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under
certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act.
The Company’s amended
and restated bylaws (the “Bylaws”) provide that the Company will indemnify and hold harmless, to the fullest extent
permitted by Section 145 of the DGCL, as amended from time to time, each of its directors and officers, and may indemnify its employees
and agents as set forth in the DGCL.
The DGCL permits a corporation
to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation
or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:
| ● | any breach of the director’s duty of loyalty to
the corporation or its stockholders; |
| ● | acts or omissions not in good faith or which involve intentional misconduct or a knowing violation
of law; |
| ● | payments of unlawful dividends or unlawful stock repurchases
or redemptions; or |
| ● | any transaction from which the director derived an improper
personal benefit. |
The Company’s restated
certificate of incorporation and Bylaws provide that, to the fullest extent permitted by applicable law, none of our directors
will be personally liable to us or our stockholders for monetary damages. Any repeal or modification of this provision will be
prospective only and will not adversely affect any limitation, right or protection of a director of our company existing at the
time of such repeal or modification.
We have also obtained
liability insurance for our directors and officers that insures our directors and officers, within the limits and subject to the
limitations of the policy, against certain expenses in connection with the defense of actions, suits or proceedings, and certain
liabilities that might be imposed as a result of such actions, suits or proceedings, to which they are parties by reason of being
or having been directors or officers. We may apply for insurance on behalf of any director, officer, employee or other agent for
liability arising out of his or her actions, whether or not the DGCL would permit indemnification.
We have entered into indemnification
agreements with our directors and officers whereby we have agreed to indemnify our directors and officers to the fullest extent
permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director
or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director,
officer, employee or agent of the Company, provided that such director or officer acted in good faith and in a manner that the
director or officer reasonably believed to be in, or not opposed to, the best interest of the Company. At present, there is no
pending litigation or proceeding involving a director or officer of the Company regarding which indemnification is sought, nor
is the registrant aware of any threatened litigation that may result in claims for indemnification.
See also the undertakings
set out in response to Item 17 herein.
Item 16. Exhibits
|
|
|
|
|
|
Incorporated
by
Reference |
Exhibit
No. |
|
Exhibit
Description |
|
Filed
Herewith |
|
Form/
File No. |
|
Date |
3.1 |
|
Restated Certificate of Incorporation
of the Registrant |
|
|
|
S-8 |
|
03/17/14 |
3.2 |
|
Certificate of Designation of
Preferences, Rights and Limitations of Series C Convertible Preferred Stock |
|
|
|
8-K |
|
07/06/22 |
3.3 |
|
Certificate of Amendment to the
Restated Certificate of Incorporation |
|
|
|
8-K |
|
09/08/20 |
3.4 |
|
Amended and Restated Bylaws of
the Company |
|
|
|
8-K |
|
06/17/22 |
4.1 |
|
Reference is made to Exhibits
3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7 and 3.8. |
|
|
|
|
|
|
4.2 |
|
Specimen stock certificate for
common stock |
|
|
|
8-K |
|
04/03/09 |
4.3 |
|
Form of Indenture |
|
X |
|
|
|
|
4.4 |
|
Form of Debt Security* |
|
|
|
|
|
|
4.4 |
|
Form of Warrant |
|
|
|
8-K |
|
02/21/20 |
4.5 |
|
Form of Unit* |
|
|
|
|
|
|
4.6 |
|
Common Stock Warrant, dated as
of July 5, 2022 |
|
|
|
8-K |
|
07/06/22 |
5.1 |
|
Opinion of Latham & Watkins,
LLP |
|
X |
|
|
|
|
10.1 |
|
Securities Purchase Agreement
dated as of July 5, 2022 |
|
|
|
8-K |
|
07/06/22 |
10.2 |
|
Registration Rights Agreement
dated as of July 5, 2022 |
|
|
|
8-K |
|
07/06/22 |
23.1 |
|
Consent of Latham & Watkins,
LLP
(included in Exhibit 5.1) |
|
X |
|
|
|
|
23.2 |
|
Consent of BDO USA, LLP Independent
Registered Public Accounting Firm |
|
X |
|
|
|
|
24.1 |
|
Power of Attorney (included on
signature pages to the registration statement) |
|
X |
|
|
|
|
* To be filed by amendment
hereto or pursuant to a Current Report on Form 8-K to be incorporated herein by reference.
Item 17. Undertakings
(a) The undersigned Registrant hereby undertakes:
(i) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(A) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(B) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the
most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information
set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered
(if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or
high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant
to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate
offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
(C) To include any material information with respect to the plan of distribution not previously disclosed in the registration
statement or any material change to such information in the registration statement;
provided, however, that
paragraphs (a)(1)(i), (ii), and (iii) of this section do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section
13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or
is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
(ii) That, for the purpose of determining any liability under the Securities Act of 1933, each such post- effective amendment
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.
(iii) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
at the termination of the offering.
(iv) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
(A) Each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement
as of the date the filed prospectus was deemed part of and included in the registration statement; and
(B) Each
prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on
Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information
required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement
as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale
of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and
any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement
relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration
statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by
reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with
a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement
or prospectus that was part of the registration statement or made in any such document immediately prior to the effective date;
or
(v) That, for the purpose of determining liability of the Registrant under the Securities Act of 1933 to any purchaser in the
initial distribution of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the undersigned
Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser,
if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned Registrant
will be a seller to the purchaser and will be considered to offer and sell such securities to such purchaser:
(A) Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant
to Rule 424;
(B) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred
to by the undersigned Registrant;
(C) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned
Registrant or its securities provided by or on behalf of the undersigned Registrant; and
(D) Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.
(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of
1933, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange
Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of
the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers
and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that
in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities
Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than
the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the
successful defense of any action, suit or proceeding), is asserted by such director, officer or controlling person in connection
with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.
(d) The undersigned registrant hereby undertakes that:
(i) For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus
filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant
pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement
as of the time it was declared effective.
(ii) For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains
a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering
of such securities at that time shall be deemed to be the initial bona fide offering thereof.
Signatures
Pursuant to the requirements
of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in San Diego, California, on September 9, 2022.
|
By: |
/s/ David J. Marguglio |
|
|
David J. Marguglio |
|
|
Chief Executive Officer |
Power of Attorney
KNOW ALL PERSONS BY THESE
PRESENTS, that each person whose signature appears below hereby constitutes and appoints David Marguglio and David Benedicto, and
each of them singly, as such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution,
for such person and in such person’s name, place and stead, in any and all capacities, to sign any or all amendments (including,
without limitation, post-effective amendments) to this registration statement (or any registration statement for the same offering
that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits
thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact
and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about
the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming
all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done
by virtue hereof.
Pursuant to the requirements
of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the
dates indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ David J. Marguglio |
|
Chief Executive Officer and Director |
|
September 9, 2022 |
David J. Marguglio
/s/ David C. Benedicto |
|
(Principal Executive Officer)
Chief Financial Officer |
|
September 9, 2022 |
David C. Benedicto
/s/ Richard C. Williams |
|
(Principal Financial and Accounting Officer)
Chairman |
|
September 9, 2022 |
Richard C. Williams
/s/ Howard C. Birndorf |
|
Director |
|
September 9, 2022 |
Howard C. Birndorf
/s/ Meera J. Desai |
|
Director |
|
September 9, 2022 |
Meera J. Desai |
|
|
|
|
|
|
|
|
|
/s/ Vickie Reed |
|
Director |
|
September 9, 2022 |
Vickie Reed |
|
|
|
|
|
|
|
|
|
ADAMIS PHARMACEUTICALS CORPORATION
697,674 Shares of Common Stock
Underlying Series C Convertible Preferred Stock
750,000 Shares of Common Stock Underlying Warrants
PROSPECTUS
,
2022